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ABSTRACT 
 
Yuhang Jiang: Block ionomer complex formulations for in vivo protein delivery 
 (Under the direction of Alexander Kabanov) 
 
Complex coacervation between therapeutic proteins and hydrophilic ionic-neutral 
block-copolymers leads to the formation of core-shell structured nanoparticles gently 
packaging the proteins in its core (reviewed in CHAPTER 1). This kind of nanoparticle, termed 
block ionomer complex (BIC), has great potential as protein delivery vehicles because of its 
simple and non-denaturing manufacturing procedure. However, reports on in vivo application 
of protein BICs are not common, primarily because of their instability at physiological ionic 
strength. The focus of this thesis is to explore the usage of BIC as an in vivo protein delivery 
vehicle. 
Our lab previously developed a protein BIC formulation, “SOD1 nanozyme”, formed 
between the protein superoxide dismutase 1 (SOD1) and the block copolymer poly(ethylene 
glycol)-poly(L-lysine) (PEG-PLL) followed by crosslinking with 3,3'-
dithiobis(sulfosuccinimidyl propionate) (DTSSP). CHAPTER 2 examines the mechanism for 
SOD1 nanozyme to be effective for stroke treatment. Active incorporation of SOD1 nanozymes 
into the growing thrombus turns out to retain them at the vicinity of the injured sites on blood 
vessels after stroke.  
Although helpful in the retention of SOD1 nanozymes after stroke, polylysine can be 
toxic in vivo because of their cationic charge which easily disrupts cellular membranes. 
CHAPTER 3 describes a project that aims to replace the polylysine component with poly 
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(aspartate diethyltriamine) (PAsp(DET)). This polymer is less toxic than polylysine due to its 
unique two-step protonation behavior, and its BIC with SOD1 has a similar size as the PLL-
based SOD1 nanozyme. The therapeutic efficacy of this new formulation is also close to that 
of the PLL-based formulation.  
This dissertation also involves the characterization of a protein BIC formulation without 
crosslinking. We found that the BIC formed by brain derived neurotrophic factor (BDNF) and 
PEG-poly (L-glutamic acid) is stable at physiological salt concentrations. While protecting the 
cargo BDNF from interaction with a variety of mucosal proteins, the complex specifically 
releases active BDNF in the presence of its receptor, tropomyosin receptor kinase B (TrkB). 
Compare with native BDNF, The complex delivered significantly higher amounts of protein to 
different brain regions after intranasal delivery. This work is presented in CHAPTER 4. 
In summary, BIC is a promising platform for in vivo delivery of therapeutic proteins with 
careful design of stabilization strategies.  
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CHAPTER 1 INTRODUCTION1 
During the past decade, therapeutic proteins (e.g. antibodies, hormones, enzymes, and 
vaccines) have rapidly emerged as mainstream drug candidates in the pharmaceutical industry. 
Many new protein drugs are under investigation, raising hope for curing a large number of 
diseases previously considered “incurable” such as cancer, stroke, diabetes, etc. Nonetheless, 
not all proteins are naturally good drug candidates. Indeed, many of the most potent therapeutic 
proteins cannot make it to the clinic due to in vivo enzymatic degradation, rapid clearance from 
the circulation, immunogenicity, and inability to cross cellular membranes. To address these 
problems, a carrier is necessary to protect the proteins, facilitate their transport through 
biological barriers, and deliver them to their target site(s) of action. Microparticles composed 
of poly(lactic-co-glycolic acid) (PLGA) are the most well established carrier for protein 
delivery. With the controlled degradation of the polymeric matrix, the proteins encapsulated in 
the PLGA particles can be slowly released over a period of time [1]. Considering PLGA 
particles can be engineered to remain in the circulation for a long time [2], this approach can 
generate a sustained release profile for the cargo proteins after a single injection. The 
disadvantage of this approach is the extensive use of organic solvents in the manufacturing 
process which usually leads to denaturation or inactivation of the proteins [3]. Moreover, a 
large faction of proteins are usually associated with the surface of the microparticles and are 
not completely encapsulated. Once injected, these proteins will quickly dissolve in the blood 
stream and result in a sudden peak serum exposure, a phenomenon also known as “burst 
                                                 
1 Part of This chapter previously appeared as a manuscript soon to be submitted. 
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release” which can associate with serious adverse events for some protein therapeutics [4]. 
Therefore, new strategies are needed for protein delivery to overcome these limitations.  
1.1 Block Ionomer Complex 
Nearly 90 years ago, Bungenberg de Jong and Kruyt first reported the phenomenon of 
“complex coacervation”[5] where the mixing of two oppositely charged colloids in aqueous 
solution lead to phase separation [6]. This phenomenon was later suggested as a pre-cellular 
structure and therefore the “origin of life” by Oparin [7]. Complex coacervation between 
oppositely charged polyelectrolytes has extensive applications in the food and pharmaceutical 
industries for separation processes. However, it was not until the mid-1990s when researchers 
started to realize that the coacervation process can be thermodynamically confined within well 
dispersed compartments, simply by extending one or both the polyelectrolytes by an uncharged 
hydrophilic polymer block [6, 8, 9]. The introduction of this hydrophilic block transforms the 
phase separation process into micellization, making it a powerful tool for therapeutic delivery 
of small molecules [10], genetic materials [11], as well as proteins [12, 13]. Indeed, the 
microenvironment and phase behavior of the coacervates strikingly resemble the membrane-
less protein bodies in the cytoplasm formed by RNA and proteins [14, 15]. Hence, they 
represent a natural protein packaging mechanism, and offer a very gentle immobilizing 
environment for proteins to stay in the coacervate core protected by the hydrophilic corona. 
The production of block ionomer complexes (BICs) eludes any exposure to organic solvents, 
a significant advantage over the commonly used PLGA-based microspheres/nanoparticles. 
This chapter aims to review the physical roots of BIC formation, unique properties of protein 
BICs, common methods to stabilize protein BICs, and their biomedical applications. There are 
currently four terms in use interchangeably to describe this system: interpolyelectrolyte 
complex (IPEC) [16], complex core coacervate micelle (C3M) [6], polyion complex (PIC) [9], 
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and BIC [8]. For the sake of clarity, the term “block ionomer complex” will be employed 
throughout this thesis. 
1.1.1 Formation of BIC 
Electrostatic interaction is widely accepted to be the driving force for BIC formation 
[8, 9]. It generally comprises two components: the coulombic attraction between opposite 
charges, and the release of small counter ions originally condensed by the polyelectrolytes. 
Other non-covalent forces, like hydrophobic interactions and hydrogen bonding, have also been 
reported to contribute to the formation of BICs depending on the chemical nature of 
polyelectrolytes as well as solution environments (e.g. pH, ionic strength, etc.) [17]. A recent 
report suggest that even strong cation-π interactions can drive the formation of BICs from two 
like-charged polyelectrolytes by overcoming longer-range electrostatic repulsion [18]. The 
contribution of these non-electrostatic interactions can be more prominent if BICs are formed 
in environments where the electrostatic interactions are inhibited (e.g. solutions of high ionic 
strength).  
Thermodynamically, the spontaneous formation of BIC entails a negative change in 
total Gibbs free energy (∆G) of the system, which is further determined by the balance between 
changes in system entropy (-T∆S) and enthalpy (∆H). A considerable body of literature has 
been published over the past two decades [9, 19, 20] discussing how individual events 
contribute to entropic and enthalpic changes depending on the nature (strong vs. weak) and 
charge density of the polyelectrolytes, as well as pH, temperature, and ionic strength of the 
solution. In most systems, this process is primarily driven by favorable entropic gains related 
to the release of pre-condensed small counter-ions and water molecules upon complexation 
[19, 21-25], as evidenced by the endothermal signals observed in isothermal titration 
calorimetry experiments [19, 25]. This effect is counterbalanced by unfavorable entropic 
changes originating from immobilization of polyelectrolytes upon complexation and formation 
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of highly ordered water networks at the colloidal interface [26]. The formation and rupture of 
hydrogen bonds is the major contributor for the enthalpic change in the system, which is usually 
determined by the dehydration/rehydration at the complex interface as well as direct formation 
of hydrogen bonds between the polyelectrolytes [26].  
1.1.2 Protein BICs 
As natural polyelectrolytes, many proteins can spontaneously participate in the 
formation of BICs with oppositely charged block ionomers in the aqueous solution. This 
process is usually described as “self-assembly”, and is arguably the simplest way to load 
proteins into a nanoparticle. The same driving forces and thermodynamic considerations 
discussed in the previous section also apply here. Nevertheless, interactions between proteins 
and linear polyelectrolytes are featured by some unique properties due to the structural rigidity 
and charge anisotropy of the proteins. 
1.1.2.1 Structural rigidity 
Most globular proteins have well-defined high order structures with limited 
conformational flexibility. As a result, their partner polyelectrolytes have to be flexible enough 
for the binding to be stable [27-29]. Hatorri et al. observed a reciprocal relationship between 
binding affinity (Kobs) and polymer persistence length (Lp) in the complexation between β-
lactoglobulin and three different polyanionic polymers [30]. Furthermore, even with a highly 
flexible polymer, the precise compensation to the local charge distribution of a protein can 
result in a great loss in its configurational entropy which is unfavorable for BIC formation. 
Indeed, many protein BICs are formed at non-stoichiometric charge ratios, and there is usually 
no noticeable change in its major physical properties at charge stoichiometry [13, 31, 32]. This 
implies the existence of unsaturated charges on either or both species that cannot be accounted 
for by complementarity of each other. These unsaturated charges are presumably compensated 
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by small ions in the solution, which in fact renders the microenvironment of the BIC core highly 
hydrated [17] and more amenable for protein storage.  
1.1.2.2 Charge anisotropy 
Another unique feature setting proteins apart from other polyelectrolytes is their 
heterogeneous distribution of positive and negative charges on the surface. When the charges 
exist as localized clusters, they become the so-called “charge patches” [33]. This concept is 
initially introduced in the field of ion-exchange chromatography where proteins can bind to the 
stationary phases even when the mobile phase pH is on the “wrong side” of the protein 
isoelectric point (pI) [34]. Indeed, when the dimension of protein globules are comparable or 
longer than the Debye length (κ-1) in the solution, their charge patches will be isolated from 
each other, and interact with polyelectrolytes individually [35]. In this scenario, the 
complexation between polyelectrolyte to a protein under conditions where both species have 
the same sign of net charge [30, 36, 37] can occur as a consequence of “patch”-mediated short-
range electrostatic attractions overcoming long-range repulsion from other “patches”[38]. In 
light of the highly differential charge distribution pattern of proteins, this effect makes it 
possible for a polyelectrolyte to specifically recognize and isolate a particular protein from a 
mixture of same-charged proteins [39]. 
1.2 Environmental effects on protein BICs 
1.2.1 Ionic strength (I) 
As introduced in the previous section, electrostatic interaction is the predominant force 
driving the formation of BICs. The increase of ionic strength suppresses it by decreasing the 
Debye length in water, as demonstrated by the following equation [40]. 
𝜅−1 =
0.304
√𝐼
 
It is then tempting to extrapolate a monotonic dependence of BIC stability on ionic 
strength of the solution. Interestingly, both experimental observations [38, 41, 42] and 
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computer simulation results [43] suggest that the binding constant between protein and 
polyelectrolyte do not simply decrease with the increase of I, but instead usually displays a 
maximum in the range of 5mM < I < 30mM [38].  
This phenomenon cannot be simply explained by hydrophobic interaction or hydrogen 
bonding because their effects on polyelectrolyte binding are usually overshadowed by 
electrostatic interaction at such low ionic strength. Actually, while high ionic strength leads to 
screening of electrostatic interaction between the protein and the polyelectrolyte, a low level 
of ionic strength is necessary to isolate the “charge patches” on the protein. As I value continues 
to decrease below 5mM, the Debye length will significantly increase. When it reaches a level 
comparable to the dimension of the protein globule, the repulsive effects between the 
polyelectrolyte and same-charged “patches” on the protein starts to take effect and destabilize 
the complex [38]. Similar consideration applies to the polyelectrolytes - a certain level of ionic 
strength is necessary to screen the repulsion between charges of adjacent repeating units on the 
polymer. When the ionic strength is low, these repeating unites will try to maximize their 
distances between each other, which subsequently increases the stiffness of the polymer [44]. 
As discussed in the previous section, this effect is unfavorable for its binding to proteins. 
Hence, the formation and stability of BIC requires a moderate level of ionic strength in the 
solution. 
1.2.2 pH 
Most proteins are weak polyelectrolytes with pI values ranging from 4 – 10 [45]. 
Therefore, solution pH closely modulates the density and distribution of protein surface 
charges, as well as the protonation status of the polyelectrolytes. Subsequently, gradual changes 
in solution pH have been shown to induce sequential changes in physical states of the 
coacervation core and ultimate disassembly of the complex in a number of protein-
polyelectrolyte systems [46-49]. This feature makes protein BICs potentially advantageous as 
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delivery tools since variations in local pH is common in biological systems, especially under 
pathological conditions. For instance, endosomal pH drops from 6.8 – 4.9 during its maturation 
process [50]; tumor microenvironment usually features slightly acid pH ranging from 6.9 – 6.5 
[51] and ischemic stroke also induces a quick drop of brain tissue pH from 7.0 to 6.2  [52].  
1.2.3 Temperature 
The effect of temperature on protein BICs is highly system-dependent and usually 
reflects the contribution of non-electrostatic interactions. In general, higher temperature 
upholds hydrophobic interaction, while lower temperature favors hydrogen bonding [53]. 
Nevertheless, temperature fluctuation in the physiologically relevant range (36oC – 43oC) 
usually do not make a big difference for most protein BICs. Exceptions are those formulated 
with a class of temperature-responsive polymers as the hydrophilic block, including poly-
(isopropylacrylamide) (PNIPAAM) [54] and poly-(isopropyl oxazoline) (PiPrOx)[55]. This 
class of polymers have lower critical solution temperatures (LCST) that are above room 
temperature, and become insoluble at elevated temperatures. As a result, protein BICs  formed 
using these polymers whose hydrophilic block can undergo temperature-induced phase 
transition can selectively release the cargo proteins at certain temperatures [56]. By chemically 
modifying these polymers, their LCST can be tuned close to body temperature (35oC – 40oC) 
[57, 58]. This is particularly useful for targeting inflamed or tumorous tissues where the tissue 
temperature is higher than normal. Another exciting application of this class of BICs is in 
combination with far infrared irradiation to create local hyperthermia and induce drug release 
at virtually any tissue of interest [59]. 
1.3 Stabilization of protein BICs 
Although many protein BICs can maintain their physical characteristics for months in 
a low-salt buffer (5mM-30mM), colloidal stability is the primary challenge associated with 
BIC for its biomedical application in vivo.  Physiological fluids typically have an ionic strength 
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of about 150mM to maintain homeostasis, which readily disassembles most protein BICs 
before they can reach their target sites of action. In many cases, additional engineering is 
necessary to stabilize protein BICs and effectively use them for in vivo protein delivery. These 
engineering approaches include chemical crosslinking, charge conversion, ternary complex 
formation, and introduction of hydrophobic interactions. 
1.3.1 Chemical crosslinking 
Chemical crosslinking is the most common way to stabilize BICs for in vivo protein 
delivery. With the introduction of small crosslinkers into the system, the electrostatic coupling 
between protein and polymer can be reinforced by covalent conjugation, thereby preventing 
the BIC from dissociation in the body fluids. Depending on the need for proteins to be released 
at the target site, the crosslinker can be designed to be environmentally sensitive.  
Glutaraldehyde is one of the earliest crosslinkers for proteins. Despite the simplicity of 
its structure, it demonstrates very complicated chemical behaviors in solution depending on the 
pH, temperature and concentration [60]. Consequently, its crosslinking chemistry usually 
involves a combination of several different mechanisms such as Schiff base formation and 
Michael-type addition. Despite this complexity, glutaraldehyde crosslinks BICs primarily by 
reacting with amine groups on lysine and arginine residues on the protein or the polymer. The 
reaction can also be followed by the addition of reducing agents such as sodium borohydride 
(NaBH4) or sodium cyanoborohydride (NaCNBH3) in order to stabilize the double bonds in 
the Schiff base [61-64]. These BICs demonstrated superb stability and therapeutic efficacy in 
vivo. However, glutaraldehyde has long been criticized for being too heterogeneous and toxic 
for medical applications[65]. 
Alternative to glutaraldehyde for protein BIC stabilization are amine-reactive bi-
functional crosslinkers, including N-hydroxysuccinimide (NHS) esters and imidoesters. Both 
of them contain highly reactive leaving groups that can be substituted upon nucleophilic attacks 
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from the primary amine groups on either the protein or the polymer, with slight differences in 
optimum pH of the reaction. Sometimes disulfide bonds are introduced in these crosslinkers 
(3, 3’-Dithiobis (sulfosuccinimidylpropionate), DTSSP or Dimethyl dithiobispropionimidate, 
DTBP) to facilitate red-ox mediated cargo release [13, 32, 63, 66].  
In light of the proximity between negatively charged carboxylate groups and positively 
charged amine groups in many protein BIC systems, 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC) can be used as a zero-length crosslinker. This 
reagent activates carboxyl groups for spontaneous reaction with primary amines and result in 
the formation of a peptide bond. Its crosslinking efficiency can be further increased if used in 
combination with NHS or sulfo-NHS [67]. 
Crosslinking can also be mediated by chemical modifications on the polymer. In this 
scenario, the crosslinking chemistry is usually designed to be sensitive to environmental 
changes. As an example,  Hefferman et al. reported a strategy where the amine groups of 
poly(ethylene glycol)-poly(L-lysine) (PEG-PLL) are modified with crosslinkable 
dithiopyridine groups with Michael addition which preserves the positive charges on the PLL 
chain [68]. This modified polymer successfully encapsulated succinimidyl 3-(2-pyridyldithio) 
propionate (SPDP)-modified ovalbumin/catalase through disulfide bond formation.  
One potential downside of crosslinking is the immobilization of proteins in the core of 
the BIC with limited to no freedom of movement. This could be a disadvantage for the delivery 
of growth factors or antibodies which requires complementary binding with receptors or 
antigens to exert their functions. Nevertheless, crosslinking are most suitable for the delivery 
of enzymes with small substrates that can freely diffuse into the core of BIC without the need 
of having the enzymes released [12, 13, 32, 61, 63, 69-71]. The crosslinking of autolytic 
enzymes like trypsin in the BIC also prevents them from digesting each other, which is 
beneficial for their storage [62]. Protein activity loss is one of major concerns with crosslinking. 
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It can usually be ameliorated by careful selection of chemistry and optimization of input ratio 
of crosslinkers to reactive chemical groups on the protein. Indeed, a number of reports 
suggested insignificant loss of protein activity after crosslinking compared with their non-
crosslinked counterparts [61, 62, 71].  
1.3.2 Charge conversion  
The primary reason for the instability of protein BICs at the physiological ionic strength 
is its insufficient charge density compared to synthetic polymers or DNA molecules. Therefore, 
charge conversion or “supercharging”[72] of proteins has been explored to increase BIC 
stability. The idea is to increase the charge density on the protein by converting positively 
charged amine groups into negatively charged carboxylate groups or vice versa. This approach 
was first reported by Lee et al. using citraconic amide and cis-aconic amide to modify the lysine 
groups on equine heart cytochrome c (Mw = ~12kD) [73]. The modification effectively 
converted the pI value of the protein by about 6, and as a result, effectively formed stable BICs 
with PEG–poly[N-[N’-(2-aminoethyl)- 2-aminoethyl] aspartamide] (PEG-pAsp(DET)) in a 
solution of 150mM NaCl. These BICs were effectively internalized by HuH-7 cells in vitro, 
where the citraconic amide and cis-aconic amide were hydrolyzed in the acidic endosomal 
environment. The cytochrome c then reversed its charge again and dissociated with PEG-
PAsp(DET), which further disrupted endosomal membrane and facilitated the endosomal 
escape of cytochrome c. Soon after this work, a much bigger protein, an antibody (Mw = 
~150kD) against the nuclear pore complex, was delivered to the cytoplasma of living HuH-7 
cells in the same manner, and successfully inhibited their growth [74]. Recently, this system 
was further optimized by Kim et al  in terms of the number of charge conversion sites and the 
ratio of homopolymer/block copolymer in the BIC,  in order to develop it into a platform 
technology for intracellular antibody delivery [75]. 
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1.3.3 Ternary BICs 
In addition to directly participating in the complex coacervation process, proteins have 
also been reported to partition into the coacervate core of complexes composed of a charged-
neutral block copolymer and an oppositely charged homopolyelectrolyte. The resulting 
complex are more stable against disintegration upon increases in ionic strength [76-80]. To 
prepare these complexes, the proteins are usually pre-mixed with a like-charged 
homopolyelectrolyte and then transferred to a solution containing an oppositely charged block 
copolymer. This process leads to the formation of a ternary BIC system containing the protein, 
the homopoyelectrolyte, as well as the block copolymer. It is also named “tripartite polyion 
micelles” in some works [81, 82]. The amount of proteins loaded into the complex can be 
modulated by complex composition, NaCl concentration and the starting concentrations of the 
protein [80]. Furthermore, the protein can be gradually released from the complex upon 
increasing ionic strength in the solution without destruction of the BIC structure [77, 78]. It is 
observed that the most stable complex formation occurs at an excess of homopolyelectrolyte 
over the protein [76]. As a result, the major limitation of ternary BIC is loading capacity. For 
example, in a lysozyme/ poly(acrylic acid)-poly(acryl amide) /poly(N,N-dimethylaminoethyl 
methacrylate) ternary system, the optimal number of lysozyme molecules was estimated to be 
5–15 per complex [76]; in a lipase/ PEG-poly(2-methyl vinyl pyridinium)/ poly(acrylic acid) 
system, this number is 0.4-4.6, depending on the ionic strength of the solution [77]. 
1.3.4 Introducing hydrophobic interactions 
Although electrostatic interaction is the primary driving force of BIC formation, one 
cannot ignore the contribution from forces of other nature, such as hydrogen bonding and 
hydrophobic interactions in maintaining its structural stability. Indeed, one strategy to stabilize 
BIC is the introduction of hydrophobic interactions at the coacervate core. Yuan et al. observed 
increased stability in solutions containing up to 0.1M NaCl of a BIC complex made from 
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lysozyme and PEG – poly (aspartic acid) (PEG-PAsp) by adding a single hydrophobic group 
to the ω-end of the PAsp block. Pispas further introduced hydrophobic monomers into the 
backbone of a block copolymer, which forms stable complexes with lysozyme in a solution 
containing 0.15 M NaCl [83]. 
1.4 Application of protein BICs 
1.4.1 Intracellular delivery  
Unlike small molecule drugs, most proteins cannot diffuse through the cellular 
membrane. Therefore, a delivery system that can transfer protein pharmaceuticals into the 
cytoplasm is the key for successful protein therapies with intracellular targets. To this end, BIC 
offers a great opportunity given its proven success in intracellular delivery of DNA and RNA 
molecules [84, 85].  
The major technical challenge for proteins to be delivered in this way involves striking 
the right balance between the stability of BIC and the ability to release active proteins in the 
cytoplasm. To this end, chemical crosslinking is generally not a good stabilization strategy 
unless the crosslinker can be designed to be environmentally responsive and degrade to release 
the encapsulated proteins. As an example, crosslinkers can be designed to degrade and release 
cargo proteins inside the cells, taking advantage of the biochemical gradients between the 
cytoplasm and the extracellular space [32]. For example, the reduced form of glutathione 
(GSH) predominantly exists in the cytoplasm, creating a reductive environment in sharp 
contrast to the oxidizing environment of the extracellular space [86]. Hence, BICs crosslinked 
with disulfide bonds can release vaccine antigens inside the endosomes of antigen presenting 
cells [68]. Besides, protein BICs stabilized by charge conversion [74, 87] and ternary complex 
formation have also been reported to be successfully utilized for intracellular protein delivery 
[81, 82]. 
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Another challenge involves endosomal escape of the proteins. As BICs are internalized 
into a cell, they immediately become entrapped in endosomes and will be later degraded by 
lysosomal enzymes [88]. To avoid degradation and ensure cytosolic delivery of the proteins, 
their endosomal escape needs to be facilitated. Kataoka et al. reported the use of PEG-block-
poly [N-[N′-(2-aminoethyl)-2-aminoethyl] aspartamide] (PEG−PAsp(DET)) copolymer, 
which destabilizes endosomal membranes in the low pH environment [89], and successfully 
delivered charge-converted antibodies to the cytosol [74, 75].  
1.4.2 Enzyme delivery 
BIC is particularly useful for the delivery of enzymes, which is attributed to its “caging” 
and “hyperactivation” effects. Crosslinking is the major strategy to stabilize BICs for enzyme 
delivery, because release is usually not necessary for them to work. 
1.4.2.1 Caging 
BICs are known to protect the cargo proteins from proteolysis and aggregation induced 
by shear stress and temperature [90]. This is attributed to the steric repulsion provided by its 
hydrophilic corona against proteolytic enzymes and other proteins. Nonetheless, the highly 
hydrated nature of the coacervate core [17] allows for entry of small substrates and exit of 
products, which makes it a semi-permeable “cage” that allows the enzyme to be functional 
without being released out of the complex. The “cage” can be further fortified by chemical 
crosslinking and used for in vivo enzyme delivery [12, 13, 32, 91].  
Formation of “cages” can also extend the circulation time of enzymes in vivo. The size 
of many proteins are smaller than the cut-off value of glomerular filtration (~45kD) and are 
therefore easily excreted from the kidney [92]. Some cationic proteins are quickly captured and 
removed by the mononuclear phagocyte system (MPS) and accumulate in the liver, spleen and 
lung shortly after administration [93]. Incorporation into “cages” effectively increases the 
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hydrodynamic size and shields the cationic charge of these enzymes, resulting in longer 
retention in the circulation. 
1.4.2.2 Hyperactivation 
Although enzymes can lose their activity towards large substrates (e.g. cell walls of 
bacteria [94]) owing to the caging effect, small substrates can usually diffuse into the 
coacervate core and access the active sites on the enzymes even after crosslinking [12, 70, 71, 
95, 96]. Interestingly, sometimes compartmentalization of enzymes into BICs can lead to 
increased activity over their native counterparts, which is typically referred to as 
“hyperactivation” [70, 71, 97-100]. The mechanism for hyperactivation differs case by case, 
but typically involves contributions from the block copolymer. For example, PEG-PAsp has 
been proposed to increase trypsin activity by direct stabilization of its histidine residues at the 
active site through electrostatic interactions[100]. In another study, the activity of lysozyme 
was doubled after encapsulation into PEG-PAsp, attributing to the condensation of substrates 
in the hydrophilic corona of the BIC [70]. More recently, Kurinomaru et al studied the 
enzymatic activity of α-chymotrypsin and reported its increase by approximately 1 order of 
magnitude after complexation with polyelectrolytes of opposite charge to its substrates, 
suggesting a substrate accumulation mechanism by electrostatic attraction [98]. A similar but 
milder increase in activity was observed in Copper/Zinc superoxide dismutase after 
complexation with PEG-poly (L-lysine) [32, 63].  
1.5 Conclusion 
With decades of research directed towards understanding the process of complex 
coacervation between proteins and polyelectrolytes, we can now take advantage of this 
phenomenon to develop protein BICs for their delivery. The electrostatic nature of the 
interaction offers a gentle environment for protein packaging, as well as great flexibilities for 
the design and control of the physical properties of the BICs. By modulating the chemical 
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composition of polymers, crosslinkers, or even the surface residues on the proteins, this 
delivery system exhibits outstanding responsiveness to subtle environmental changes that are 
relevant to pathological states. One possible next step could be the functionalization of the 
BICs for cell-targeted delivery of proteins. 
On the other hand, our understanding on the fundamental principles of protein BIC 
formation is still limited. Currently it is difficult to predict whether a BIC can form between a 
particular set of protein and polymer, and how stable they can be in a given environment due 
to the complexity of the system. This is can be hopefully achieved by in situ simulations with 
the rapid advancement of computing power. 
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CHAPTER 2  SOD1 NANOZYME SALVAGES ISCHEMIC BRAIN BY LOCALLY 
PROTECTING CEREBRAL VASCULATURE2 
2.1 Summary 
Copper/zinc superoxide dismutase (CuZnSOD; SOD1) is widely considered as a 
potential therapeutic candidate for pathologies involving oxidative stress, but its application 
has been greatly hindered by delivery issues. In our previous study, nano-formulated SOD1 
(cl-nanozyme) was shown to decrease infarct volume and improve sensorimotor functions after 
single intravenous (IV) injection in a rat middle cerebral artery occlusion (MCAO) model of 
ischemia/reperfusion (I/R) injury. However, it remained unclear how cl-nanozyme was able to 
deliver SOD1 to the brain and exert therapeutic efficacy. Present study aims to answer this 
question by exploring micro-distribution pattern of cl-nanozyme in the rat brain after stroke. 
Immunohistochemistry studies demonstrated cl-nanozyme co-localization with fibrin along 
damaged arteries and capillaries in the ischemic hemisphere. We further found that cl-
nanozyme can be cross-linked into thrombi formed after I/R injury in the brain, and this effect 
is independent of animal species (rat/mouse) used for modeling I/R injury. This work is also 
the first report reinforcing therapeutic potential of cl-nanozyme in a well-characterized mouse 
MCAO model of I/R injury. 
2.2 Introduction 
Stroke affects 7 million people, and continues to kill over a hundred thousand people 
annually in the United States alone [101]. Main causes of brain tissue damage during transient 
                                                 
2 Part of this chapter previously appeared as an article in the Journal of Controlled Release. The 
original citation is as follows: Jiang, Yuhang et al., J Control Release. 2015 September 10; 
213: 36–44. doi:10.1016/j.jconrel.2015.06.021. 
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ischemic stroke are ischemic and reperfusion injuries. Ischemic injury results from lack of 
glucose and oxygen when blood flow to the brain is blocked [102]. Reperfusion injury results 
from the detrimental action of reactive oxygen species (ROS) on brain tissue after blood flow 
is restored [103]. 
Antioxidant enzymes are endogenous tools for cells to scavenge ROS.  However, their 
expression is often inhibited during stroke [104, 105], rendering antioxidant activity far less 
than sufficient for complete removal of excess ROS. Therefore, supplementation of antioxidant 
enzymes to the brain is a potential therapeutic strategy for this disease [106]. Their action would 
be especially beneficial for rescuing the salvageable penumbra since oxidative stress is the 
main mechanism of tissue damage in this area [107]. A direct use of anti-oxidant enzymes as 
therapy for stroke is not plausible because of its short half-life in the blood and poor 
permeability across the blood-brain barrier (BBB) and cellular membranes [108]. Even though 
BBB can be partially compromised during and after stroke, it still remains the key impediment 
for CNS transport of enzymes [109, 110]. Multiple strategies have been explored for delivery 
of functional antioxidant enzymes to the brain, including cationic liposomes, fusion proteins 
with peptide transduction domains, poly(ethylene glycol)-protein conjugates (PEGylated 
protein) and encapsulation into poly(lactic-co-glycolic acid) (PLGA) nanoparticles [111-118]. 
However, each of these approaches has limitations that precluded their successful clinical use 
as discussed in our previous work [32]. Briefly, loading of enzymes into solid or hollow 
nanoparticles often resulted in loss of activity and/or unsatisfactory loading efficiency (32% in 
the case of SOD1 liposomes [119]), and PEGylation usually decreases enzyme permeability 
across BBB [113]. 
We have demonstrated a different approach for encapsulation and delivery of 
antioxidant enzymes to the brain [32, 63, 120]. This approach is based on incorporation of an 
antioxidant enzyme, such as SOD1, into nano-sized polyion complexes with cationic block 
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copolymers (“nanozymes”). Nanozymes are core-shell structured nanoparticles with the 
polyion complex core consisting of charge-neutralized polycation chains and protein globules, 
and the shell consisting of PEG chains. Primary amine groups in the core were cross-linked 
(cl) using low molecular mass chemical cross-linkers to form cl-nanozyme and further purified 
to improve sample homogeneity by removing non-cl-nanozymes [32]. This formulation is 
essentially a covalently cross-linked polyion complex formed by SOD1 and methoxy-
poly(ethylene glycol)-b-poly(l-lysine) (PEG-pLL, Figure 2.1). 
Some of the key advantages of this strategy include high (100%) loading efficiency 
(owing to the formation of stoichiometric complexes) and instantaneous enzyme availability 
for catalysis precluding the need for its release, since superoxide anions are small enough to 
freely diffuse into the enzymatic core of the particle. This is a distinct advantage in scavenging 
ROS in the acute phase of diseases caused by oxidative stress, because the time window for 
antioxidant enzymes to work in these scenarios are usually narrow, and “fast acting” 
formulations like cl-nanozyme are consequently favored over those requiring drug release 
mechanisms. 
The initial in vivo proof of concept for nanozyme transport to CNS was obtained by us 
using cl-nanozymes carrying butyrylcholinesterase, SOD1, or catalase [61, 63]. Compared to 
PEGylated SOD1 which poorly enters cells, SOD1 nanozyme was transported into neuronal 
cells and was superior to PEGylated SOD in depleting intracellular ROS and inhibiting 
Angiotensin II signaling in vitro and in vivo [121, 122]. Catalase nanozymes demonstrated 
neuroprotective effects in an animal model of Parkinson’s disease (PD) [123, 124]. Our most 
recent results demonstrated the therapeutic efficacy of purified SOD1 cl-nanozyme in a rat 
middle cerebral artery occlusion (MCAO) model of I/R injury [32] by decreasing infarct 
volume and improving sensorimotor functions after a single IV bolus. Similar to other reports 
using nano-formulated SOD1 for the treatment of stroke [115, 118], we did not specifically 
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investigate how this approach was able to exert the observed therapeutic effect [32]. However, 
understanding this mechanism can be essential for improving therapeutic potential of SOD1 
nanozyme formulation and for discovery of more applications of the nanozyme delivery 
platform. 
In the present work, we demonstrate that cl-nanozyme accumulated predominantly 
within the injured vasculature and co-localized with fibrin after stroke. This suggests one 
possible mechanism where cl-nanozyme passively target to damaged brain vasculature, and 
locally protect the neurovascular unit as an entire entity. To evaluate this finding from a 
translational perspective and investigate the validity of our findings in another animal model, 
we tested the same cl-nanozyme formulation in a well-characterized mouse model of stroke, 
and again observed significant reduction of infarct size. In vitro thrombus incorporation assay 
in the mouse plasma further supported our major hypothesis that cl-nanozyme can be actively 
incorporated into growing thrombus formed during or after stroke. 
2.3 Materials and Methods 
2.3.1 Materials. 
3,3’-Diaminobenzidine (DAB), SOD1, and 2,3,5-triphenyltetrazolium chloride (TTC) 
were purchased from Sigma-Aldrich. PEG113-pLL51 was purchased from Alamanda 
Polymers™; Bovine serum albumin (BSA), ethanol, ethylenediaminetetraacetic acid (EDTA), 
3,3´-dithiobis(sulfosuccinimidylpropionate) (DTSSP), 10% neutral buffered formalin, 
trichloroacetic acid (TCA) were purchased from Thermo Fisher Scientific. AlexaFluor® 
secondary antibodies, and Hoechst 43580 were purchased from Life Technologies; C57BL/6 
mouse plasma was purchased from Molecular Innovations. All reagents and chemicals were 
used as received. 
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2.3.2 Synthesis of cl-nanozyme. 
Cl-nanozyme was synthesized at the polycation to SOD1 charge ratio Z+/−=2 using 
DTSSP as a cross-linker as previously described [32]. After synthesis and desalting (to remove 
unreacted DTSSP), cl-nanozyme was purified to separate the cross-linked from the non-cross 
linked species. For the purification, cl-nanozyme in 10 mM HEPES buffer containing 0.3 M 
NaCl (pH=7.4) was loaded onto Macrosep centrifugal device (Pall Corporation, MI) and 
concentrated twice to about 10% of its initial volume by centrifugation at 4,500 rpm at 4 °C. 
The concentrate was collected and desalted using NAP™ columns to remove excess NaCl. The 
eluent was then collected in 10 mM HEPES buffer containing 0.15 M NaCl (pH=7.4). SOD1 
enzyme activity was determined using a microplate version of PG assay [32], and normalized 
to protein content determined by Inductively Coupled Plasma Mass Spectrometry (ICP-MS) 
using copper and zinc as standards. Particle effective diameter (z-average hydrodynamic 
diameter) and polydispersity index (PDI) were measured using a Malvern Zetasizer Nano 
(Malvern Instruments Ltd., MA). The resulting cl-nanozyme had a particle diameter of 39.2 ± 
0.8 nm (PDI < 0.1), and retained 58.6 ± 9.5% enzyme activity relative to native SOD1. 
2.3.3 Animals. 
Charles River Laboratories supplied 8-week-old male Sprague-Dawley rats (250-300 
g), and 12-week-old male C57BL/6 mice (20-28 g). Animals were housed and humanely 
handled in accordance with the Principles of Animal Care outlined by National Institutes of 
Health. They were allowed free access to food and water and were maintained under 
temperature, humidity, and light-controlled conditions. Institutional Animal Care and Use 
Committees (IACUC) of University of Nebraska Medical Center (UNMC) and the University 
of North Carolina at Chapel Hill approved all experiments involving animal subjects.   
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2.3.4 MCAO model of transient ischemic stroke in rats. 
Brain ischemia was modeled by transient MCAO method as described previously [125]. 
Rats were anesthetized with ketamine (80 mg/kg) and xylazine (5 mg/kg) cocktail and 
isoflurane (5% v/v for induction and 0.5% v/v during surgery). Rectal temperature was 
maintained at about 37 °C throughout the surgery using a homoeothermic monitor (Harvard 
Apparatus, UK). Animals were prepared for surgery according to IACUC recommendations. 
The right common carotid artery was exposed and occluded using a silicon rubber-coated 
monofilament for MCAO. Filament was inserted through the incision into internal carotid 
artery (ICA) and further until reaching the bifurcation of MCA. Tip occluded the entrance to 
MCA and blocked blood supply to part of the right brain hemisphere (referred to as the 
ischemic hemisphere). Filament was carefully withdrawn after 1 hour. Sham surgery was 
performed as described above without filament insertion. After the surgery, animals were 
returned to their cages and allowed free access to water and food. At the time of reperfusion, 
10,000 U/ kg of native SOD1 or cl-nanozyme (n = 10 in each group) were IV injected under 
anesthesia. Rats were sacrificed 3 or 24 h post-reperfusion, and perfused with 4% 
paraformaldehyde solution for histology analysis.  
2.3.5 Histology and Immunohistochemistry. 
Tissue toxicity of cl-nanozyme was assessed by hematoxylin and eosin (H&E) staining 
of liver, spleen, kidney, and lung tissues. Tissue samples were dissected and fixed in 10% 
neutral buffered formalin before embedded in paraffin. Five μm thick tissue sections were 
processed and stained according to standard protocol used by Tissue Sciences core facility at 
UNMC. Cl-nanozymes were visualized in peripheral organs using DAB. Tissue samples were 
prepared as described above. For detection of cl-nanozyme in liver, spleen, kidney, and lung, 
respective tissue sections were incubated at 4 oC overnight with rabbit anti-PEG antibody 
(1:500, Abcam, MA), followed by incubation with secondary biotinylated goat anti-mouse 
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antibodies  and VecStain Elite kit (Vector Laboratories,  CA). DAB color generation system 
was used as described previously [126] for chromogenic visualization. Fluorescent 
immunohistochemistry study was performed on tissues perfused with PBS followed by 10% 
neutral buffered formalin. To visualize cl-nanozyme in the liver and brain, tissue sections were 
stained using rabbit anti-PEG antibody (Abcam, CA) diluted 1:200 and 1:100, respectively. 
Hepatocytes were detected with polyclonal chicken anti-albumin antibody (1:100, Sigma 
Aldrich, MO). CD68+ cells in the brain (infiltrating monocytes), liver (Kupffer cells) and spleen 
(splenic macrophages) were visualized using monoclonal mouse anti-CD68 antibody (1:40 
Abcam, MA). Brain microvessels were visualized using monoclonal mouse anti-CD31 
antibody (1:30, AbD Serotec, NC); neurons were visualized using monoclonal mouse anti-
neurofilament 70kDa (NF-L) antibody (1:200, Millipore, CA); fibrin deposits after stroke were 
visualized using mouse anti-fibrin antibody (1:50, Abcam, MA). Treatment with primary 
antibodies was followed by treatment with secondary antibodies: AlexaFluor 594 goat anti-
chicken, AlexaFluor 594 goat anti-mouse, and AlexaFluor 488 goat anti-rabbit, and AlexaFluor 
647 goat anti-mouse. Nuclei were visualized using 2.5µg/ml Hoechst 43580 solution. 
Immunofluorescence were detected using Zeiss 710 Confocal Laser Scanning Microscope and 
images were analyzed using Zeiss Zen software and ImageJ software (National Institute of 
Health, MD). 
2.3.6 Preparation of 125I-labeled Proteins and cl-nanozyme. 
Native SOD1, fibrinogen, BSA, or cl-nanozyme were radioactively labeled with 125I 
using chloramine-T method as previously described [127]. Briefly, 5 µg of protein or 
equivalent amount of cl-nanozyme was mixed with 0.5 mCi Na125I (PerkinElmer, MA) in a 
final volume of 40 μL in sodium phosphate buffer (0.25 M, pH=7.5). Five μL freshly-made 
chloramine-T solution (2 µg/µL in sodium phosphate buffer) was added to the mixture. After 
60 s incubation under constant mixing, the 125I-labeled samples were purified using Illustra 
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NAP-5 desalting columns (GE Healthcare, NJ). Fractions were collected in Eppendorf tubes 
pretreated with 1% BSA in Lactated Ringer’s solution (1% BSA-LR) to prevent non-specific 
adsorbance. Radioactivity was measured using a PerkinElmer γ-counter. TCA precipitation 
was conducted to determine the 125I association of labeled samples. Briefly, 1 µL of collected 
fractions was added to 0.5 mL of 1% BSA-LR and then precipitated in 0.5 mL of 30% TCA 
followed by centrifugation at 5000 xg for 10 min at 4 °C. The resulting supernatant and pellet 
were measured in the γ-counter and the values were used to calculate the %radioactivity that 
precipitated with acid (% protein bound-125I = [CPMpellet /(CPMpellet + CPMsupernatant)]*100%). 
Samples containing >100,000 cpm/µL of radioactivity and > 90% TCA precipitation were used 
for animal studies.  
2.3.7 Biodistribution and Serum Clearance in Mice. 
Twelve-week-old male C57BL/6 mice were anesthetized by intraperitoneal (IP) 
injection of 0.2 mL of urethane (4.0 g/kg). Approximately 500,000 CPM of radiolabeled 
samples were injected IV via the jugular vein with 0.2 mL of 1% BSA-LR.  For the 
biodistribution study, the abdomen and rib cage were opened and venous blood was collected 
by cardiac puncture 1 hour post-injection. Then, 20 mL of PBS was perfused through the left 
ventricle of the heart. At the end of study, organs were dissected and wet-weighed. For the 
serum clearance study, blood from the pre-exposed carotid artery was collected at various time 
points after injection. Serum was separated from whole blood by centrifugation at 5400 xg for 
10 min at 4 oC. Levels of radioactivity were measured in the γ-counter. To calculate serum 
clearance, the level of radioactivity was expressed relative to the amount injected (%Inj/mL) 
and these values were plotted against time (min) to construct the serum concentration vs. time 
curve. 
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2.3.8 MCAO Model of Transient Ischemic Stroke in Mice. 
All mice were randomly assigned before surgery into one of the following groups: cl-
nanozyme-treated group (n = 8), native SOD1-treated group (n = 8), or saline-treated group (n 
= 7). The mice were weighed and were subjected to 90 min of ischemia under isoflurane 
anesthesia (5% v/v for induction and 1.5% v/v during surgery) as previously described [128]. 
Briefly, rectal temperature was monitored maintained at approximately 37 °C during surgery 
using a homoeothermic heating system. A midline ventral neck incision was made, and 
unilateral MCAO was performed by inserting a silicone rubber coated monofilament into the 
right internal carotid artery 6 mm from the internal carotid/pterygopalatine artery bifurcation 
via an external carotid artery stump. At the time of reperfusion, 10,000 U/ kg of treatment 
solutions were IV injected under anesthesia.  
2.3.9 TTC Staining and Brain Infarct Volume Quantification. 
After 90 minutes of ischemia and 24 hours of reperfusion, the mice were euthanized 
and the brains were chilled at -80 °C for 4 minutes to slightly harden the tissue. Five 2-mm-
thick coronal sections were cut from the olfactory bulb to the cerebellum and then stained with 
1.5% TTC in PBS (pH=7.4). The sections in TTC solution were incubated in a water bath 
maintained at 37 °C for 30 minutes, then transferred to a 10% phosphate-buffered formalin 
solution and incubated overnight at 4 °C before pictures were taken for analysis. The infarct 
volumes were calculated blinded to the treatment given, and the infarct size in each of the five 
slices was quantified using the Image J software. In addition to total hemisphere, the infarct 
areas were determined separately for cortex and caudoputamen in each slice. Then the infarct 
areas on each slice were summed up and multiplied by thickness to calculate infarct volumes. 
The infarct volumes were calculated using Swanson’s method [129] and processed as % 
contralateral hemisphere to avoid mis-measurements secondary to edema. 
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2.3.10 Thrombus Incorporation Assay in Mouse Plasma. 
One hundred thousand CPM of 125I-labeled fibrinogen, BSA, native SOD1, and cl-
nanozyme were added into an Eppendorf tube containing 1 mL C57BL/6 mouse Lithium 
heparin-stabilized plasma (Innovative Research, MI). Half mg of protamine sulfate was then 
added to neutralize heparin and allow thrombus formation. The tube was incubated on a rotary-
shaker for 24 h at 4 °C before centrifugation at 5000xg for 10 min. Serum was separated from 
the white thrombus at the bottom of the tube, and then subjected to TCA precipitation assay to 
correct for error caused by 125I dissociation during incubation as described above. Percentage 
of samples sequestered in the thrombus compartment were calculated using the following 
formula: %Thrombus Incorporation = [CPMthrombus /(CPMthrombus + CPMserum)]*100%. 
2.3.11 Autoradiography 
For autoradiography experiments, 125I-labeled cl-nanozyme was IV injected in mice 
with either a MCAO surgery at the onset of reperfusion or a sham surgery. The mice were 
sacrificed and perfused with PBS 1 hour after injection. Their brains were then harvested, snap-
frozen with dry ice, and cut into 50 µm-thick coronal sections before exposing it for 73 days 
before read on an autoradiography imager.  
2.3.12 Statistical Analysis. 
The randomization code was broken in the mice stroke therapeutic efficacy study after 
acquiring all the data. Statistical analysis was done using Prism 5.0 software (GraphPad, CA). 
Unpaired Student's t-test was used for two groups, and one-way ANOVA followed by Tukey’s 
multiple comparison test for groups of three and above. A minimum p-value of 0.05 was 
estimated as the significance level. Results of all experiments are presented as mean ± standard 
error of the mean (SEM).  
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2.4 Results 
2.4.1 Cl-nanozyme Tissue Distribution in the Rat MCAO Model of I/R Injury 
In our previous paper [32] reporting synthesis and purification of cl-nanozyme, we have 
demonstrated decreased infarct volume and improved sensorimotor functions after a single IV 
injection in a rat MCAO model. To gain insight into the mechanism of cl-nanozyme’s 
therapeutic efficacy, we studied its micro-distribution in the same model. 
Immunohistochemistry (IHC) analysis revealed accumulation of cl-nanozyme primarily in the 
ipsilateral hemisphere in the area of infarct at 3h post-reperfusion. (Figure 2.2). 
Cl-nanozyme localized primarily within blood vessels, as shown by fluorescent double 
staining for cl-nanozyme and endothelial marker PECAM-1 in Figure 2.3 A. Cl-nanozyme 
staining outside the blood vessel in brain parenchyma was primarily seen in the infarct region 
of the ipsilateral hemisphere. Cl-nanozyme co-localized with neither neurons nor activated 
mononuclear phagocytes (Figure 2.2).   
We further hypothesized that cl-nanozyme co-localize with damaged blood vessels, 
since its signal was most prominent in infarct regions. Evidence for this hypothesis is shown 
in Figure 2.4. During the MCAO procedure, occlusion is created by filament insertion into the 
lumen along the internal carotid artery. Figure 2.4 A is a confocal micrograph of a coronal 
brain section across a portion of internal carotid artery where the filament tip was positioned 
(Figure 2.4 D).  
The filament tip had damaged the artery during filament insertion and/or occlusion, as 
suggested by discontinuous nuclear staining around the luminal side of the artery (Figure 2.4 
C), and cl-nanozyme co-localized with these damaged portions of the artery (Figure 2.4 B, C). 
No cl-nanozyme signal was observed in the contralateral hemisphere where the internal carotid 
artery was not damaged, as shown in dotted box, Figure 2.4 B. In infarcted brain regions, cl-
nanozyme co-localized with fibrin, a protein involved in blood clotting (Figure 2.3 B, C), 
27 
which further supports our hypothesis that cl-nanozyme localizes in damaged blood vessels. 
Interestingly, while most cl-nanozyme signal co-localized with fibrin, not all capillaries with 
fibrin deposition sites showed cl-nanozyme accumulation (Figure 2.3 C).  
Peripheral organs were collected 24 hours after reperfusion, and histological 
examinations was performed to qualitatively study the disposition and any possible toxicity 
effects of cl-nanozyme. H&E-stained tissue sections did not reveal any sign of acute toxicity 
(Figure 2.5). Analysis of cl-nanozyme distribution in select peripheral organs confirmed its 
presence in the liver and spleen, but not in lungs or kidneys at this time point (Figure 2.6 A). 
Triple fluorescent immunostaining of the liver tissue revealed co-localization of cl-nanozyme 
with hepatocytes and Kupffer cells (Figure 2.6 B). We noticed intense cl-nanozyme staining 
in areas between two adjacent hepatocytes indicative of its deposition in the bile canaliculi, 
suggesting a potential clearance mechanism via bile excretion. In addition to their intracellular 
accumulation in hepatocytes, cl-nanozymes were also observed in liver sinusoids. 
2.4.2 Cl-nanozyme Biodistribution and Serum Clearance in Mice 
We studied biodistribution of native SOD1 and cl-nanozyme in healthy C57/B6 mice 
to determine the effects of formulating SOD1 on its biodistribution. One hour after injection, 
cl-nanozyme was found to accumulate in liver and spleen in significantly higher amounts than 
native SOD1, displaying 25- and 38-fold increases, respectively (Figure 2.7 A). Changes in 
SOD1 accumulation in most other peripheral organs including heart, lung, and spine were 
significant but less drastic (less than 4-fold increase) compared to liver and spleen. However, 
cl-nanozyme accumulation in kidney was reduced by more than half compared to native SOD1 
(35.4% vs. 88.3%). Notably, the brain uptake of cl-nanozyme was 2-fold higher than native 
SOD1 (0.0809% vs. 0.0406%) in healthy mice. 
First-order kinetics was observed in the early phase of clearance for both substances, 
demonstrated by the statistically significant relation between log(%Inj/mL) and time (Figure 
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2.7 B). Serum half-life (t1/2) of native SOD1 and cl-nanozyme was 10.3 min and 33.8 min 
respectively, suggesting prolonged SOD1 circulation after formulation. 
2.4.3 Therapeutic Effect of cl-nanozyme in Mouse MCAO Model of I/R Injury 
Cl-nanozymes administered at the onset of reperfusion in a mouse MCAO model of I/R 
injury resulted in reduced infarct volumes compared to groups treated with saline or native 
SOD1. Significantly reduced infarct volume was observed in all three brain regions analyzed 
(cortex: 35.0±7.0%; caudoputamen: 13.0±4.7%; hemisphere: 28.1±5. 6%) compared to those 
injected with saline (cortex: 69.8±3.7%; caudoputamen: 73.7±6.0%; hemisphere: 61.5±6.8%) 
and native SOD1 (cortex: 59.3±7.7%; caudoputamen: 78.9±6.5%; hemisphere: 57.1±6.9%), as 
shown in Figure 2.8. The mean infarct volume was slightly lower in the native SOD1-treated 
group than in saline-treated group, albeit this difference was not statistically significant. 
Interestingly, the protective effect of cl-nanozyme appears to be stronger in the caudoputamen 
area than in the cortex or entire hemisphere. 
2.4.4 Thrombus Incorporation Assay 
To directly evaluate the ability of cl-nanozyme and native SOD1 to be incorporated into 
white thrombi, we performed an in vitro thrombus incorporation assay using mouse plasma. 
After 24 h incubation at 4 oC, incorporation of native SOD1 into the thrombi (4.4±0.4%) was 
not significantly different from that of the negative control, BSA. However, significantly more 
cl-nanozyme (8.2±0.2%) was sequestered in the thrombus compartment (Figure 2.9). 
Fibrinogen was used as a positive control and showed 52±4% accumulation in the thrombi.  
2.5 Discussion 
Cl-nanozyme for delivery of antioxidant enzymes has been successfully used by us 
previously for the treatment of multiple pathologies involving oxidative damage [32, 120-124, 
130]. Specifically, its therapeutic effect in decreasing the infarct volume and improving 
sensorimotor functions upon single IV injection in a rat stroke model was demonstrated in our 
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laboratory [32]. The present study continues to explore the mechanism by which cl-nanozyme 
exerted therapeutic efficacy.  
The structure of cl-nanozyme does not include a brain targeting moiety. Thus, we did 
not expect it to cross a healthy BBB. Initially we believed that cl-nanozymes could possibly 
enter the brain via the disrupted BBB, a well-characterized phenomenon after brain I/R injury 
[131-133]. To our surprise, despite the observed therapeutic efficacy in the stroke model, we 
did not observe substantial evidence of cl-nanozyme crossing the BBB. In the IHC 
experiments, we did observe a considerable amount of cl-nanozyme signal associated with the 
infarct region of the brain, where the BBB is supposed to be disrupted. However, the majority 
of the signal was not associated with neurons or activated macrophages, but trapped inside the 
lumen of blood vessels. Although by design, our study does not exclude the possibility of a 
small portion of cl-nanozyme crossing the BBB and exerting therapeutic effect, the hypothesis 
of thrombus accumulation is apparently more plausible based on our observations. It also 
serves better on explaining why cl-nanozyme shows much better therapeutic efficacy compared 
to native SOD1, which can be tricky to explain based solely on the BBB disruption theory.  
Our thrombus incorporation hypothesis is derived from the chemical composition of cl-
nanozyme, with its core structure being charge-neutralized pLL/SOD1 complex. The monomer 
of pLL, ϵ-lysine is capable of cross-linking into the thrombus by participating in biochemical 
reactions accompanying its formation [134]. Briefly, blood vessel damage activates platelets 
and initiates a cascade of tissue factor (TF) activation, which converts TFXIII to its active form, 
TFXIIIa. TFXIIIa is a transglutaminase which cross-links glutamine with the ε-amine group of 
lysine. Indeed, pLL has been proved to be a good substrate for transglutaminase and this 
reaction has been utilized to enzymatically produce pLL-protein conjugates [135]. Therefore it 
is not surprising to see this reaction occurring in vivo. 
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IHC data in the rat model strongly supported the thrombus incorporation hypothesis. 
Cl-nanozyme was detected primarily in the infarct region in association with endothelial cells 
of the damaged brain vasculature. Intense cl-nanozyme signal was observed only in areas 
surrounding the injured internal carotid artery, but not the healthy one in the contralateral 
hemisphere (Figure 2.4 B), confirming the selective nature of the association between cl-
nanozyme and damaged blood vessels. Evidence of cl-nanozyme and thrombus crosslinking 
was further supported by the co-localization of cl-nanozyme with fibrin, a major component in 
blood clots, in the capillaries of the infarct region.  
Beyond the brain, we have also examined cl-nanozyme distribution in select peripheral 
organs. H&E data suggested that cl-nanozyme is not noticeably toxic after in vivo 
administration. This is a promising observation that supports further development of such 
nanoparticles for stroke therapy. IHC experiments found massive distribution of cl-nanozyme 
into liver and spleen. This is generally in agreement with the known function of these organs 
in clearing particulate matter.  Interestingly, a closer look at the liver slices revealed distribution 
of cl-nanozyme not only in Kupffer cells, but also in tube-shaped territories between two 
adjacent hepatocytes that resemble bile canaliculi. This particular staining pattern possibly 
indicates that cl-nanozyme is excreted through bile as part of its metabolic pathway. What we 
have detected in these structures is more likely to be metabolic products than intact cl-
nanozymes, especially considering the time point of analysis (24 h after reperfusion) and the 
cleavable disulfide bond present in the cross-linker (DTSSP) used in this formulation. Notably, 
the rat liver has been reported to have rather high concentrations (10 mM) of reduced 
glutathione known to participate in disulfide reduction, which thereby may enhance 
degradation of the cl-nanozyme in the liver [32]. In addition to intra-hepatocyte accumulation, 
staining was also observed in the liver sinusoids. Considering the t1/2 of cl-nanozyme (33.8 min 
in mouse), it is unlikely that level of cl-nanozyme in the blood is high at this time point, i.e. 24 
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h after administration. Presence of cl-nanozyme in liver sinusoids may result from pLL binding 
to liver tissue, possibly via the same mechanism by which they bind to damaged blood vessels 
in the brain, since most of the blood coagulation proteins are synthesized in the liver [136].  
These results in the rat MCAO model indicate that the therapeutic effect of cl-nanozyme 
can be attributed to its specific accumulation into damaged blood vessels in the infarct region. 
In events where blood vessels were damaged, intrinsic mechanisms of thrombosis could take 
place and actively recruit cl-nanozyme into them, thereby effectively reducing oxidative stress 
generated at the vicinity of damaged sites. Such blood vessel damage could result either from 
mechanical force (filament damaging ICA) or I/R injury (endothelium damage), both occurring 
in the MCAO model of stroke and the latter can also take place after transient stroke suffered 
by human subjects [137]. Since this mechanism appears to be translatable to human patients, 
we moved forward and investigated utility of cl-nanozymes in a different species to determine 
if similar therapeutic outcomes can be achieved in the mouse model of I/R injury. Indeed, this 
work is the first report reinforcing therapeutic potential of cl-nanozyme in a well-characterized 
mouse MCAO model [138]. 
Before evaluating cl-nanozyme in the mice MCAO model, we first conducted a 
comprehensive study to determine cl-nanozyme biodistribution in the early phase (1h) after 
injection. Similar to the rat model, we observed significantly increased sequestration of cl-
nanozyme in the liver and spleen compared to native SOD1. Reduced uptake of cl-nanozyme 
in the kidney compared to that of native SOD1 (32 kDa) is in general agreement with the known 
function of kidney (glomerular filtration) in clearing small molecules with a molecular mass 
cutoff of ~40 kDa. Tissue distribution of protein is generally increased after formulation in 
most other organs, including a significant 2-fold increase in the brain. This increase probably 
resulted from a combination of decreased kidney accumulation and increased serum half-life 
as shown in Figure 2.7 B. 
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Remarkably, cl-nanozyme administration resulted in significant reduction of infarct 
size in the mouse MCAO model compared to the native SOD1 group reinforcing its therapeutic 
potential in a second rodent model. Formation of micro-thrombi in capillaries after MCAO 
surgery is a well-documented phenomenon in rodent MCAO models [137, 139, 140]. 
Specifically, Zhang and colleagues [141] reported fibrin deposition primarily in the sub-cortex 
region after acute ischemic stroke, which may explain why therapeutic effect of cl-nanozyme 
is more pronounced in the caudoputamen compared to the cortex. Therefore, we speculate that 
the mechanism of action of cl-nanozyme involves local protection of cerebral vasculature. 
Since the damaged brain endothelium in I/R injury is a site of intense ROS production [142], 
retention of cl-nanozyme in the sites of vascular damage and thrombus formation can facilitate 
its ability to scavenge local ROS and to subsequently mitigate detrimental effects of ROS on 
vasculature. Autoradiography results suggest clear differences in the distribution pattern of cl-
nanozyme injected before and after stroke (Figure 2.10 Autoradiography of brain slices after 
IV injection of 125I labelled cl-nanozymeFigure 2.10). The distribution of cl-nanozyme in the 
stroke brain spreads the entire stroke hemisphere, while in the healthy brain they appears to be 
restrained in the brain ventricles. 
From a translational research perspective, clinically, different factors can contribute to local 
thrombus formation during the reperfusion phase of focal cerebral ischemia, as described by 
Virchow’s triad: reduction in cerebral blood flow, damage to the vessel wall, and 
hypercoagulability. These events can contribute to the occurrence of focal “no-reflow” 
phenomenon [143] and even thromboembolic complications in the sub-acute phase of ischemic 
stroke [144]. In our thrombus incorporation study, we clearly demonstrated that cl-nanozyme 
can be actively incorporated into thrombus during their growth. This experimental set up is a 
simplified model where only white thrombi are formed.  It can be postulated that in the scenario 
of clinical stroke where body temperature, blood cells, and platelets are all contributing to 
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thrombus formation, the rate and extent of cl-nanozyme incorporation into thrombus could be 
faster and greater. By exploiting the “no-reflow” phenomenon and by passively accumulating 
at the site of injured arteries and microvessels after reperfusion, it is not surprising that cl-
nanozyme exerted better therapeutic outcomes than native SOD1. Furthermore, passive 
targeting to sites of thrombus formation may open avenues for the delivery of agents that 
protect the endothelium from negative side effects of thrombolytics such as recombinant tissue 
plasminogen activator (rt-PA).  
Two key works reported the use of particulate carriers for the delivery of SOD1 to treat 
stroke. Reddy and Labhasetwar demonstrated a 65% decrease in infarct volume compared to 
saline-treated group when SOD1 encapsulated in PLGA nanoparticles (NPs) was delivered via 
intracarotid (IC) injection to a rat MCAO model of stroke [115]. Interestingly, they also showed 
increased accumulation of HRP-loaded NPs in the ischemic hemisphere compared to its non-
ischemic counterpart similar to our observation on increased accumulation of cl-nanozyme in 
the ischemic hemisphere. The authors pointed out the need for further research to understand 
the mechanism of NP-mediated protection. Yun et al. also showed a 50-60% decrease in infarct 
volume when SOD1 was delivered (again via the IC route) using 3 different nanoparticle 
platforms (liposomal SOD1, Polybutylcyanoacrylate-SOD1 and PLGA-SOD1 particles) in a 
mouse MCAO model of stoke [118]. SOD1 was conjugated to the distal end (mPEG2000-DSPE) 
of liposomes prepared using phosphatidylcholine, cholesterol, mPEG2000-DSPE, and MAL-
PEG2000-DSPE (molar ratio of 55:39:4:2). These carriers were modified with anti-NMDA 
receptor antibodies for brain targeting, and was shown to protect the ischemic regions by 
suppressing caspase-3 activation.  
Although the present study is not unique in exploring therapeutic effect of SOD1 nano-
formulations, it draws attention to the delivery of therapeutics to the neurovascular unit as a 
whole and in particular to the damaged brain endothelium, rather than neurons alone. Often 
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researchers focus extensively on the delivery of therapeutics across the BBB to the brain 
parenchyma, a task that remains a formidable challenge in most cases. However, it can be not 
as formidable to target therapeutics to the BBB itself. Indeed, homeostatic interactions exist 
between endothelium and cerebral parenchyma, and the BBB has been considered to be neuro-
protective on its own by excreting neurotrophic factors in response to injury [145]. Our 
observations document that cl-nanozyme accumulates into damaged brain vasculature regions 
and probably exerts its effect mainly on brain vasculature rather than the parenchyma. It 
provides evidence that targeting therapeutics to the BBB itself could also be a viable therapeutic 
strategy. Another advantage of our approach is the use of IV administration route, which can 
be more desirable than IC from a translational perspective. This is made possible 
collaboratively by increased serum half-life and additional local retention at the damaged sites 
of vasculature. Moreover, our approach of drug administration after ischemic episode, as 
opposed to pretreatment with SOD1 formulations, as reviewed by Margaill et al.[106], is 
advantageous from translational standpoint as well.  
2.6 Conclusion 
In conclusion, the present study demonstrates the ability of cl-nanozyme to accumulate 
in damaged blood vessels. This allowed therapeutic cargo to exert its effect at the interface of 
blood and brain especially vulnerable to oxidative stress in stroke. We believe that cl-nanozyme 
is a promising delivery strategy that can find application in the therapy of cerebrovascular 
conditions associated with oxidative stress and inflammation. Evaluation of cl-nanozyme 
safety and efficacy in alternate models of transient ischemic stroke, e.g. MCAO procedure 
conducted on aged animals and/or animals with co-morbidities, is essential for further 
validation of the translational potential of this work.  
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2.7 Future directions 
In this work we use an ischemic-reperfusion model to demonstrate the ability of cl-
nanozyme to locally protect the blood vessels in the brain against reperfusion injury. This 
model has intrinsic limitations in its translational potential. For example, this model utilizes a 
surgical filament to mimic the blockage of the blood vessel and the thrombolysis process during 
stroke, and the thrombolysis is complete since they are induced by removal of the filament. In 
clinical practice, however, thrombolysis is usually performed by infusion of recombinant tissue 
plasminogen activator (rtPA) [146]. Therefore, the scenario where a stroke patient receives 
complete blood reperfusion is not common. Many of them has only partial reperfusion after 
treatment, and some of the patients might not even be eligible for rtPA treatment if they were 
hospitalized too late. Consequently, it would be very attractive to test cl-nanozyme in other 
stroke models than the one we are currently using. 
Such studies can also provide valuable information on indirect mechanisms for stroke 
pathology as well as on broadening the range of indications of cl-nanozyme in stroke treatment. 
In a permanent occlusion model where the blood vessel is blocked for the entire duration of 
study, the damage mechanism would be completely different [147] and IV infusion of cl-
nanozyme could be explored as a strategy to inhibit systemic ROS signaling and subsequent 
immune responses. An embolus or laser-induced stroke model followed by rtPA infusion could 
mimic a more clinical-relevant scenario where more variables are introduced, such as the 
patient response to anti-thrombolytic therapy, the time between stroke and treatment, and the 
risk of rtPA-related hemorrhagic transformation. In these models, more therapeutic potentials 
of cl-nanozyme can be possibly explored, e.g. to extend the therapeutic window of rtPA, or as 
a pre-treatment before a stroke attack.  
If cl-nanozyme proves to work in these models, it will likely involve other mechanisms 
than the one we demonstrated in this chapter. Indeed, as an anti-oxidant enzyme formulation, 
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it is probably for cl-nanozyme to work through multiple pathways. One possibility would be 
the blockage of immunological cascade after stroke since ROS have been demonstrated to 
activate extensive immune response which exacerbates stroke damage. Another possible 
pathway is by inhibiting iron-catalyzed ROS production, since red blood cells contain a large 
amount of iron, which can promote the production of ROS as a catalyst after lysis of the cell. 
Another limitation of this work relates to the strategy of using SOD as the therapeutic 
agent, since SOD is known to cause toxicity at higher dose and therefore can generate a “bell-
shaped” dose-response curve. Concerns with SOD overdose can be traced back to the year 
1973 when Fridovich and Hodgson demonstrated that SOD-catalysed dismutation reaction of 
O2
- was reversible according to thermodynamics [148] and reported inactivation of Cu,Zn-SOD 
by H2O2 [149] as well as the peroxidation mediated by SOD on a wide variety of compounds 
[150].  The mechanism they proposed involved the reduction of the SOD Cu2+ to Cu+ by H2O2 
followed by Cu+ mediated Fenton’s type reaction with extra H2O2 to form OH
·
, which further 
oxidatively attacks an adjacent histidine and thus inactive the enzyme. This hypothesis was 
proved acceptable by many investigators later [151-153]. After the year 2000, another 
important factor HCO3
-was proved to play a vital role in Cu,Zn-SOD related peroxidation 
reactions [154, 155]. This made Dr. Fridovich write another paper[156] 30 years later to revisit 
his work published in 1973 [148]. 
However, the Cu-Zn SOD toxicity could not fully explain a series of bell-shaped dose-
response curves in vivo [157-159], because Mn SOD, which is not supposed to have peroxidase 
function, also showed similar dose-responses curves [160]. Some researchers believed it was 
trace amount of iron in vivo, maybe released from apoptotic cells that mediated similar 
Fenton’s type reactions [152]. Many researchers therefore highly recommended combination 
delivery of SOD and Catalase, and make sure they are close enough so H2O2 can be eliminated 
as soon as possible [152, 153]. 
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Another explanation for SOD toxicity is related to termination of lipid peroxidation. 
Basically, lipid peroxidation is a radical chain reaction initiated in vivo mostly by superoxide 
radical anions during stroke. Ironically, the only way to eliminate a radical is by reacting it 
with another radical, and the presence of superoxide itself as a relatively unreactive radical 
could be a perfect terminator for the lipid peroxidation chain reaction [161]. 
With the above information in mind, it is necessary to consider this effect when high 
dose of cl-nanozyme is to be used for the treatment of any disease. 
Last but not least, it is necessary to emphasize the known toxicity of poly-L-lysine for 
in vivo application. In the case of stroke, it is acceptable since this is an acute administration 
for a life-threatening condition. However, a replacement of this polymer is needed if we want 
to develop this formulation for the treatment of chronic diseases with repeated dosing regimens. 
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Figure 2.1 Schematic representation of cl-nanozyme 
This is a schematic representation of cl-nanozyme synthesis. Block ionomer complexes (BIC) 
form due to spontaneous self-assembly resulting from electrostatic binding of negatively-
charged enzyme (SOD1) with cationic block copolymer (PEG-pLL) to which DTSSP is added 
to covalently stabilize the BIC by cross-linking primary amine groups. This figure is 
reproduced from our previous publicatoin [32] to present a general idea of the cl-nanozyme’s 
structure.  
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Figure 2.2 Cl-nanozyme in the brain does not co-localize with neuron or activated 
macrophages. 
Immunofluorescent labelling reveals presence of cl-nanozyme 3h, but not 24h after reperfusion 
onset in the ischemic brain hemisphere. Distribution of cl-nanozyme in the brain is in branched 
clusters. The signal does not co-localize with mononuclear phagocyte marker CD68 or 
neuronal marker NF-L (both in pink) after stroke. Scale bar represents 20 μm. 
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Figure 2.3 Distribution of cl-nanozyme in the Rat Brain. 
Distribution of cl-nanozyme in the ipsilateral hemisphere of rat brains after I/R injury 
determined by immunofluorescence. A. Cl-nanozyme (PEG, green) was detected primarily in 
association with micro vessels (PECAM-1, red). B. Most cl-nanozyme signal co-localized with 
fibrin in rat brains after stroke, indicating possible interactions between cl-nanozyme and 
thrombus components. C. Not all fibrin signal in the brain were co-localized with cl-nanozyme. 
Nuclei are counterstained with DAPI, scale bars represent 20 μm. 
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Figure 2.4 Cl-nanozyme Accumulation in the Damaged Internal Carotid Artery (ICA). 
The ICA in the ipsilateral hemisphere in the rat brain showed intense staining for cl-nanozyme, 
which was not observed in the contralateral hemisphere. A. The ICA in the ipsilateral 
hemisphere was the only artery that showed very strong cl-nanozyme staining in the whole 
brain; B. 2.5X magnification of the squared area in A. Sub-arachnoid region shows that this 
staining was present only in the ipsilateral hemisphere, but not in the contralateral hemisphere; 
C. Confocal image of this artery shows cl-nanozyme co-localization with the injured 
endothelium cells lining the internal surface of this artery. Scale bars represent 20 μm. D. A 
graphic illustration of the position of the brain section shown in A.  
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Figure 2.5 H&E staining of peripheral organs of MCAO rats. 
Transient ischemic stroke was modeled in rats by MCA occlusion for 1 h followed by 24 h of 
reperfusion. Treatment was administered IV via the tail vein at the onset of reperfusion. 
Sections were harvested at the end of reperfusion period and examined by bright field 
microscopy at 40X magnification. Representative images for each treatment group are shown. 
Scale bar represents 50 μm. 
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Figure 2.6 Distribution of cl-nanozyme in Rat Peripheral Organs. 
Representative bright field micrographs of tissue sections harvested from MCAO rats 24 h after 
reperfusion. DAB was used to visualize cl-nanozyme in the tissue sections (black arrows).  
Scale bar represents 50 μm. B. Representative confocal fluorescent micrograph of liver tissue 
sections harvested from stroke rats 24 h after reperfusion and cl-nanozyme administration. 
Fluorescent immunohistochemistry demonstrated cl-nanozyme micro-distribution within the 
liver: red – hepatocytes; pink - Kupffer cells; green – cl-nanozyme; blue – nuclei. Scale bar 
represents 10 μm. Treatment groups are the same as shown in A. 
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Figure 2.7 Biodistribution and Serum Clearance of Native SOD1 and cl-nanozyme in 
healthy mice. 
A. C57BL/6 mice received IV bolus injection of either 125I-labeled native SOD1 (n=7), or cl-
nanozyme (n=8). One hour later organs were harvested and radioactivity was measured. 
Results represent mean % of injected dose per gram of tissue (ID%/g) with error bars 
representing ±SEM. Statistical significance was determined by Student’s t-test (indicated as 
follows: n.s., not significant; *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001); B. Serum 
clearance profiles of native SOD1 and cl-nanozyme were plotted and analyzed by linear 
regression fitting. The serum half-life was 33.8 min (R2=8966, P<0.0005; n=1-2 mice/time 
point) for cl-nanozyme, and 10.3 min (R2=8156, P<0.05; n=1-2 mice/time point) for native 
SOD1.  
45 
 
Figure 2.8 Therapeutic Efficacy of cl-nanozyme in Mice MCAO Model of I/R Injury. 
At the onset of reperfusion, 10,000 U/kg of native SOD1 (n = 8), cl-nanozyme (n = 8), or equal 
volumes of saline (n = 7) were injected through the right jugular vein of the mice under 
anesthesia. Twenty-four hours after reperfusion, mice were euthanized and their brains were 
sectioned and stained using TTC solution. A. Bar graph showing infarct volume reduction. 
Infarction (% contralateral) was quantified as described in the methods section. Data were 
analyzed using one-way ANOVA with Tukey’s post-hoc test and presented as mean ± SEM. 
Statistical significance is defined as P<0.05, and indicated by * (P<0.05), ** (P<0.01), or **** 
(P<0.0001). B. Representative coronal brain sections from animals receiving different 
treatments stained using TTC. Dark-colored areas indicate viable tissue; pale-colored areas 
indicate dead (infarcted) tissue. 
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Figure 2.9 Thrombus Incorporation Assay in Mouse Plasma. 
Native SOD1 and cl-nanozyme were labeled using 125I before incubation with mouse plasma 
for 24 h at 4 oC. The plasma was then centrifuged to separate thrombus and serum. The 
percentage of radioactivity in the thrombus compartment was calculated as described in the 
methods section. BSA and fibrinogen were also labeled and used in parallel as negative and 
positive controls. Data were analyzed using unpaired Student’s t-test and are presented as mean 
± SEM (n=4 or 5). Statistical significance is defined as P<0.05, and indicated by n.s. (not 
significant) or **** (P<0.0001)  
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Figure 2.10 Autoradiography of brain slices after IV injection of 125I labelled cl-
nanozyme 
125I labelled cl-nanozyme was IV injected in mice with or without stroke. The mice were 
sacrificed and perfused with PBS 1 hour after injection. The mice brains were sectioned and 
subjected to autoradiography analysis.    
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CHAPTER 3  SOD1 NANOZYME WITH REDUCED TOXICITY AND MPS 
ACCUMULATION3 
3.1 Summary 
We previously developed a “cage”-like nano-formulation (nanozyme) for Copper/Zinc 
Superoxide Dismutase (SOD1) by polyion condensation with a conventional block copolymer 
poly(ethylene glycol)-b-poly(L-lysine) (PEG-PLL) followed by chemical cross-linking. Herein 
we report a new SOD1 nanozyme based on PEG-b-poly(aspartate diethyltriamine) (PEG-
PAsp(DET), or PEG-DET for short) engineered for chronic dosing. This new nanozyme was 
spherical (Rg/Rh = 0.785), and hollow (60% water composition) nanoparticles with colloidal 
properties similar to PLL-based nanozyme. It was better tolerated by brain microvessel 
endothelial/neuronal cells, and accumulated less in the liver and spleen. This formulation 
reduced the infarct volumes by more than 50% in a mouse model of ischemic stroke. However, 
it was not effective at preventing neuromuscular junction denervation in a mutant SOD1G93A 
mouse model of Amyotrophic Lateral Sclerosis (ALS). To our knowledge, this work is the first 
report of using PEG-DET for protein delivery and a direct comparison between two cationic 
block copolymers demonstrating the effect of polymer structure in modulating the mononuclear 
phagocyte system (MPS) accumulation of polyion complexes. 
3.2 Introduction 
Reactive Oxygen Species (ROS) are actively involved in the pathophysiology of a 
variety of neurological disorders [162]. They cause oxidative damage to tissues by reacting 
                                                 
3 Part of this chapter previously appeared as an article in the Journal of Controlled Release. The 
original citation is as follows: Jiang, Yuhang et al., J Control Release. 2016 Jun 10;231:38-49. 
doi: 10.1016/j.jconrel.2016.02.038. 
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with lipid, protein, and DNA molecules [163]. As a primary component of the anti-oxidative 
system in the body, SOD1 has been considered a promising therapeutic candidate for 
preventing oxidative damage [164]. However, the direct use of SOD1 for therapeutic purpose 
has been hampered by the poor stability and pharmacokinetics of this protein after intravenous 
(IV) injection [165] as well as low permeability across cellular membranes [108]. Several nano-
formulations or chemical modification approaches have been proposed to protect SOD1 from 
proteolysis [113], reduce SOD1 renal clearance [116, 117, 166], increase SOD1 membrane 
permeability [167, 168], and target SOD1 to the site of disease [118]. In particular, the concept 
of “caging” SOD1 in semi-permeable nanoparticles has recently gained considerable attention 
[169-171]. In this approach the proteins are preserved inside a polymeric “cage” that enables 
unimpeded diffusion of ROS to SOD1 active site. Thereby, the encaged SOD1 is spontaneously 
available for catalyzing superoxide dismutation without the need for the release and exposure 
of the enzyme to proteinases or other components of the blood.  
We have developed such “caged” SOD1 nanoparticles (SOD1 nanozymes) [32] using 
the enzyme self-assembly with PEG-PLL followed by chemical cross-linking of the copolymer 
with 3,3'-dithiobis(sulfosuccinimidyl propionate) (DTSSP). Recently we further demonstrated 
that PEG-PLL based nanozyme passively accumulates in the micro-thrombus and effectively 
reduces infarct volumes in rodent models of ischemic stroke [12]. The promising in vivo 
therapeutic efficacy of this formulation encouraged us to explore its potential to treat ALS, 
where ROS-related damage contributes substantially to its pathogenesis [172]. 
ALS is a chronic disease and its therapy requires long-term dosing regimens. From this 
standpoint, possible toxicity due to the relatively high cationic charge density of PLL used for 
SOD1 nanozyme synthesis may be a concern. Although no acute toxicity was observed with 
the PEG-PLL based nanozyme in our stroke study during a 24 hour time frame after a single 
IV bolus [12], we decided to forego using this formulation for a chronic dosing regimen. 
50 
Possible side effects of systemic administration of cationic nanoparticles include hemolysis 
and blood clotting [173]. Such nanoparticles are also well known to accumulate in organs of 
the MPS like the liver and spleen, thereby increasing MPS burdens and decreasing drug 
bioavailability to other organs [174]. To address this problem, we replaced PEG-PLL with 
another cationic block copolymer, PEG-DET to minimize potential toxicity during treatment. 
This block copolymer, originally developed for DNA delivery by Kataoka et al., as part of 
DNA polyplexes, has shown minimal toxicity during multiple chronic dosing regimens [175-
179]. 
PEG-DET is a cationic diblock copolymer with diethyltriamine side chains, which can 
form polyion complexes with negatively charged nucleotides [89, 175, 180, 181]. In 
comparison to other existing transfection reagents (i.e. lipofectamine, polyethyleneimine, and 
cationic polymers), PEG-DET is less toxic and more effective at achieving long-term gene 
transfection [180, 182, 183]. As shown in Figure 3.1 and Figure 3.2, PEG-DET has two pKa 
values that induce stable complex formation with DNA (pKa = 9.9) and a large buffering effect 
for efficient endosomal escape (pKa = 6.1). We expect stable complex formation will protect 
SOD1 from enzymatic degradation in the bloodstream, while the buffering capacity of PEG-
DET will reduce cationic polymer-mediated toxicity. Specifically, its cytotoxicity towards 
ALS-relevant cell lines (in vitro) and MPS organ accumulation (in vivo) were of utmost interest 
before moving to efficacy studies in ALS. 
The first mouse model for ALS was developed after the identification of mutations in 
SOD1 gene in 1993 [184], and accordingly most of our knowledge of the etiology and 
pathogenesis of the disease comes from studies carried out using this animal model [185].  As 
one of the most deadly phenotypes in this model, the denervation of the neuromuscular 
junctions (NMJ) has been demonstrated to be highly associated with muscle-mitochondria-
generated ROS [186], and occurred markedly prior to the onset of clinical symptoms [187]  
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Previous work in our laboratory has also shown that peripheral administration of recombinant 
heat shock protein 70 (rHsp70) in the SOD1G93A mouse delays symptom onset and increases 
lifespan [188-190] even though rhHsp70 was localized in the muscle instead of the spinal cord 
or brain [190]. Importantly, when administration began at postnatal day (P)30, rHsp70 
promoted a significant increase in neuromuscular junction innervation at P75 [190]. 
In this study, we investigated whether peripheral administration of DET-based SOD1 
nanozyme could scavenge muscle-mitochondria-generated ROS and consequently increase 
NMJ innervation. Towards this end, we characterized the physicochemical and biological 
properties of DET-based nanozyme including size, surface charge, cytotoxicity, biodistribution 
and pharmacokinetics, and further compared them with the PLL-based nanozyme in every 
aspect. The therapeutic activity of this new formulation was first tested in a mouse middle 
cerebral artery occlusion (MCAO) model of ischemic stroke to confirm in vivo efficacy before 
moving onto a transgenic mouse model (SOD1G93A) of ALS. In the ALS experiment, the 
nanozyme was administered intraperitoneally (IP) with considerations on patient compliance 
from a translational perspective. 
3.3 Materials and Methods 
3.3.1 Chemicals. 
3,3’-Diaminobenzidine (DAB), SOD1 (from bovine erythrocytes), 2,3,5-
triphenyltetrazolium chloride (TTC), Triton® X-100, Tween-20, Dithiothreitol (DTT) and 
xylene were from Sigma-Aldrich (St. Louis, MO). PEG-PLL was purchased from Alamanda 
Polymers™ (Huntsville, AL). The PEG was 5 kDa, and the number of repeating units of PLL 
block was 51. PEG-DET was synthesized and characterized as described previously [28]. The 
PEG was 5 kDa, and the number of repeating units of the DET block was 49. Bovine serum 
albumin (BSA), 3,3´-dithiobis(sulfosuccinimidylpropionate) (DTSSP), ethanol, 
ethylene¬diamine¬tetraacetic acid (EDTA) disodium salt, 10% neutral buffered formalin, 
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trichloroacetic acid (TCA), and copper, zinc standard solutions were from Thermo Fisher 
Scientific (Rockford, IL). AlexaFluor® secondary antibodies, Dylight 594 carboxylic acid 
succinimidyl ester dye, Hoechst 43580, were from Life Technologies (Grand Island, NY).  
3.3.2 SDS-PAGE and fluorescent labeling of SOD1 protein. 
In the Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
experiment, one group of samples containing 5 μg SOD1 were diluted with Laemmli loading 
buffer (Bio-Rad, Hercules, CA), and denatured by heating at 95 oC for 5 minutes (non-reducing 
condition). With another group of sample, 20 mM DTT was added into the loading buffer and 
incubated with the samples for 30 minutes at 37 oC before heating (reducing condition). 
Samples were then loaded on 4-20% polyacrylamide gels and electrophoresed at a constant 
voltage of 200V for 90 minutes. After electrophoresis, gels were stained using Bio-Safe 
Coomassie Stain solution (Bio-Rad, Hercules, CA) following manufacturer’s protocol, and 
then imaged on a FluorChem™ E series imager (ProteinSimple, San Jose, CA) at 100ms 
exposure time.  
Fluorescent labeling of native SOD1 was performed using maleimide chemistry 
targeting the free thiol groups on SOD1. Briefly, 1mg of maleimide conjugated Dylight 594 
(Life technologies, Grand Island, NY) was dissolved in 100 µL of DMSO and added to 5 mg 
of native SOD1 dissolved in HEPES buffered saline (HBS), pH = 7.0. Reaction was performed 
overnight at 4 oC, followed by dialysis to remove the unreacted free dye. SDS-PAGE for dye-
labeled samples were run in the dark, and imaged immediately with a FluorChemTM E series 
imager with a 590/50 nm filter to record the fluorescence signal. The same gel was then stained 
with Coomassie Blue to visualize protein bands. 
3.3.3 Synthesis of PLL and DET-based nanozymes and their catalytic activity 
characterization.  
PLL-based nanozyme and DET-based nanozyme were synthesized at the polycation to 
SOD1 charge (at pH=7.4) ratio Z+/− = 2 and 1, respectively. DTSSP was used as a cross-linker 
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at stoichiometric ratio to the amount of primary amine groups on the polycation, as described 
previously [16]. After synthesis and desalting (to remove unreacted DTSSP), nanozymes were 
purified to remove any unconjugated proteins and polymers. For the purification, nanozymes 
in 10 mM HEPES buffer (pH=7.4) containing 0.15 M NaCl were loaded onto Macrosep 
centrifugal devices (Pall Corporation, Port Washington, NY) and concentrated twice to about 
10% of its initial volume by centrifugation at 4,500 rpm at 4°C. SOD1 enzyme activity was 
determined using a microplate version of pyrogallol assay [16], and normalized to protein 
content determined by inductively coupled plasma mass spectrometry (ICP-MS) using copper 
and zinc as standards.  
3.3.3.1 Potentiometric titration. 
PEG-DET (30 mg) was dissolved in 50 mL of 0.01 N HCl containing 150 mM NaCl, 
and titrated with 0.05 N NaOH containing 150 mM NaCl at 37 °C. The titrant was added in 
quantities of 50 µL after the confirmation that pH values were stabilized (minimal interval: 30 
s). In a similar manner, titration experiments of PEG-PLL (30 mg) were completed. The 
relationship between pH and the protonation degree of polycations (α) was calculated from the 
obtained titration curves.  
3.3.3.2 Dynamic light scattering (DLS). 
Intensity-mean Z-averaged particle diameter (Deff), polydispersity index (PDI), and 
surface charge (ζ-potential) were measured by using a Zetasizer Nano ZS (Malvern Instruments 
Ltd., MA). Data is presented as mean values ± standard deviation (SD) (n=3). 
3.3.3.3 Size-exclusion chromatography coupled to a multi-angle light-scattering detector 
(SEC-MALS). 
SEC-MALS was performed using a Fast Protein Liquid Chromatography system 
(FPLC, Agilent Technologies, CA). Sample was loaded on a Superdex 75 10/300 GL column 
(GE Healthcare, Rahway, NJ) to perform SEC and separate particles based on size. Phosphate-
buffered saline (PBS) with sodium azide (NaN3) (0.02% w/v), pH = 7.4 was used as eluent. 
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Scattered light was detected using an on-line connected multi-angle light-scattering DAWN 
HELEOS II detector (MALS with 18 angles) operating at a wavelength of 658 nm. The 
refractive-index increment (dn/dc) value was set at 0.185 mL/g assuming the nanozyme as a 
protein complex. Data acquisition and analysis were carried out using the Astra 6.1 software 
(Wyatt Technology Corporation, CA).  
3.3.3.4 Atomic force microscopy (AFM). 
Five μL of an aqueous dispersion of 0.01mg/mL DET-based nanozyme was deposited 
onto freshly cleaved mica (Ted Pella, CA) for 2 min, washed with water and air-dried 
overnight. AFM imaging was performed using a MFP3D system (Asylum Research, Santa 
Barbara, CA) operated in tapping mode. Particle sizes were quantified using ImageJ software 
(National Institute of Health (NIH), Bethesda, MD). 
3.3.4 Cytotoxicity assay. 
Cytotoxicity on immortalized human brain microvascular endothelial cells 
(hCMEC/D3) and immortalized mouse motor neuron cells (NSC-34) was determined using 
CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI) 
according to manufacturer’s instructions. Briefly, hCMEC/D3 and NSC-34 cells were seeded 
into different 96-well plates and cultured in 100 µL medium. When hCMEC/D3 cells reached 
100%, and NSC-34 reached 70-80% confluency, serum-free media containing the SOD1 
formulations (native, PLL and DET-based nanozymes) or free polymers (PEG-PLL and PEG-
DET) at various concentrations were added to separate wells (n=4). After 24 h of incubation, 
the cells were washed and incubated in MTS assay reagent for 1 hour before absorbance at 
490nm was measured using a SpectraMax® M5 microplate reader (Molecular Devices, CA). 
Percent (%) cell viability was calculated using the formula (Asample/Auntreated cells)×100%. 
Data represents mean ± standard error of the mean (SEM) (n=4). 
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3.3.5 Preparation of 125I-labeled proteins and nanozymes. 
Native SOD1, fibrinogen, BSA, or nanozymes was radioactively labeled with 125I using 
chloramine-T method as previously described [38]. Briefly, 5 µg of protein or equivalent 
amount of nanozyme was mixed with 0.5 mCi Na125I (PerkinElmer Life Sciences, Boston, MA) 
in a final volume of 40 μL in sodium phosphate buffer (0.25 M, pH=7.5). Five μL of freshly-
made chloramine-T solution (2 µg/ µL in sodium phosphate buffer) was added to the mixture. 
After 1 min incubation, the 125I-labeled samples were purified using Illustra NAP-5 desalting 
columns (GE Healthcare, Piscataway, NJ). Fractions were collected in Eppendorf tubes 
pretreated with 1% BSA in lactated Ringer’s solution (1% BSA-LR) to prevent non-specific 
absorbance and radioactivity was measured in a PerkinElmer γ-counter. TCA precipitation was 
conducted to determine the 125I association of labeled samples. Briefly, 1 µL of collected 
fractions was added to 0.5 mL of 1% BSA-LR and then precipitated in 0.5 mL of 30% TCA 
followed by centrifugation at 5000 xg for 10 min at 4 °C. The resulting supernatant and pellet 
were measured in a γ-counter and the values were used to calculate the % radioactivity that 
precipitated with acid (% protein bound-125I = [CPMpellet/(CPMpellet + 
CPMsupernatant)]*100). Samples containing >100,000 CPM/µL of radioactivity and >90% 
precipitation from TCA were used for animal studies.  
3.3.6 Animals. 
Charles River Laboratories (Wilmington, MA) supplied 12-week old male C57BL/6 
mice (20-28 g). Animals were housed and humanely handled in accordance with the Principles 
of Animal Care outlined by NIH. They were allowed free access to food and water and were 
maintained under temperature, humidity, and light-controlled conditions. Institutional Animal 
Care and Use Committees (IACUC) of the University of North Carolina at Chapel Hill and 
Wake Forest School of Medicine approved all experiments involving animal subjects. 
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3.3.7 Biodistribution and pharmacokinetics. 
Twelve week-old male C57BL/6 mice were anesthetized with an intraperitoneal (IP) 
injection of 0.2 mL of urethane (4.0 g/ kg). Approximately 500,000 CPM of radiolabeled 
substances was injected IV via the jugular vein in a volume of 0.2 mL LR buffer containing 
1% BSA.  
For biodistribution study, the abdomen and rib cage were opened and venous blood was 
collected by cardiac puncture at one hour post-injection of radiolabeled substances. Next, 20 
mL of 1x PBS was perfused through the left ventricle of the heart. Organs were dissected and 
wet-weighed. Levels of radioactivity were measured in a PerkinElmer γ-counter. 
 
For pharmacokinetics study, multiple-time regression analysis was applied as 
previously described [191, 192] to calculate the blood-to-tissue unidirectional influx rates (Ki). 
Blood from the carotid artery was collected between 2 to 60 min after IV injection, the mice 
were immediately decapitated, and the whole brain removed and weighed. The arterial blood 
was centrifuged at 5400 x g for 10 min at 4oC and the serum was collected. The levels of 
radioactivity in serum (50 µL) and brain samples were counted in a PerkinElmer γ-counter. 
The brain/serum ratios (μL/g) of radiolabeled substances in each gram of brain was calculated 
separately and were plotted against their respective exposure time. Exposure time was 
calculated from the following formula: 
𝐴𝑚
𝐶𝑝𝑡
=
𝐾𝑖 [∫ 𝐶𝑝(𝑡)𝑑𝑡
𝑡
0
]
𝐶𝑝(𝑡)
+  𝑉𝑖 
where Am is cpm/g of brain, Cpt is cpm/µL of arterial serum at time t, and exposure time is 
measured by the term: 
∫ 𝐶𝑝(𝑡)𝑑𝑡
𝑡
0
𝐶𝑝(𝑡)
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The linear portion of the relation between the brain/serum ratios versus Expt was used 
to calculate Ki (µl/g-min). The slope of the linearity measures Ki and is reported with its error 
term. To determine the rate of clearance of different SOD1 formulations from the serum, results 
were expressed as the percent of the injected dose (ID) in each milliliter of serum (%Inj/ml) 
and these values were plotted against time (min). 
3.3.8 MCAO model of ischemic stroke in mice. 
Experimental mice were randomly assigned before surgery into one of the following 
groups: DET-based nanozyme (n = 8), native SOD1 (n = 8), or saline (n = 7). The mice were 
weighed and subjected to 90 min ischemia under isoflurane anesthesia (5% v/v for induction 
and 1.5% v/v during surgery) as previously described [12]. Briefly, after midline ventral neck 
incision, unilateral MCAO was performed by inserting a silicone rubber coated monofilament 
into the right internal carotid artery 6 mm from the internal carotid/pterygopalatine artery 
bifurcation via an external carotid artery stump. Upon reperfusion, 10,000 U/ kg of native 
SOD1, DET-based nanozyme, or equal volumes of saline were injected through the right 
jugular vein of the mice under anesthesia.  
3.3.9 TTC staining and brain infarct volume quantification. 
After 90 min of ischemia and 24 h of reperfusion, the mice were euthanized and the 
brains were chilled at -80 °C for 4 min to slightly harden the tissue. Five 2-mm-thick coronal 
sections were made from the olfactory bulb to the cerebellum and then stained with 1.5% TTC 
in PBS (pH=7.4). The sections in TTC solution were incubated in a water bath maintained at 
37 °C for 30 min, then transferred to 10% phosphate-buffered formalin and incubated overnight 
at 4 °C before pictures were taken for analysis. The infarct volumes were calculated blinded to 
the treatment given, and in each of the five slices the infarct size was quantified using Image J 
software (NIH). In addition to total hemisphere, the infarct areas were determined separately 
for cortex and caudoputamen in each slice. Then the infarct areas on each slice were summed 
58 
up and multiplied by slice thickness to give infarct volumes. The infarct volumes were 
calculated by Swanson’s method [129] to correct for edema, and processed as % contralateral 
hemisphere to avoid mis-measurements secondary to edema. 
3.3.10 Thrombus incorporation assay.  
As described previously [12], 100,000 CPM of 125I labeled fibrinogen, BSA, native 
SOD1, and nanozymes were added into an Eppendorf tube containing 1 mL C57BL/6 mouse 
Lithium heparin-stabilized plasma (Innovative Research, MI). Half mg of protamine sulfate 
was then added to neutralize heparin and allow thrombus to form. The tube was incubated on 
a rotary-shaker for 24 h at 4 °C before centrifuging at 5000xg for 10 min. Serum was separated 
from the white thrombus at the bottom of the tube, and then subjected to TCA precipitation 
assay to correct for error caused by 125I dissociation during incubation according to the above-
mentioned method. Percentage of protein sequestered in the thrombus compartment were 
calculated using the following formula: %Thrombus incorporation = [CPMthrombus /( 
CPMthrombus + CPMserum)]*100. 
3.3.11 Methods for treatment of SOD1G93A mice. 
All animal experiments conformed to National Institutes of Health guidelines and were 
approved by the Wake Forest University Animal Care and Use Committee. Wild type females 
and SOD1G93A males [B6SJL-TgN (SOD1-G93A) 1Gur], obtained from The Jackson 
Laboratory (Bar Harbor, ME), were bred to generate SOD1G93A mice. Genotyping was 
performed with standard primers against mutant SOD1 [32, 42] Animals were injected 
intraperitoneally with 100ul of saline, native enzyme or DET-based nanozyme (5, 15 or 25 
kU/kg) three times a week starting at P28-P32, and sacrificed at P75 to determine 
neuromuscular junction (NMJ) innervation as described below. 
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3.3.12 NMJ innervation. 
For counting innervated hind limb skeletal muscle NMJs, immunohistochemistry was 
performed on soleus and TA muscles. Animals were deeply anesthetized and transcardially 
perfused with 2% paraformaldehyde in 0.1 M sodium phosphate buffer. The muscles were 
dissected, rinsed twice with PBS and placed in 20% sucrose for at least 72 hours at 4oC. The 
muscles were embedded in 20% sucrose:OCT (2:1), cut at 30μm on the cryostat., and the 
sections were stained for the vesicular acetylcholine transporter (VAChT; Santa Cruz 
Biotechnology, Santa Cruz, CA) and neurofilament light chain (NF-L; Santa Cruz 
Biotechnology, Santa Cruz, CA). Alexa-fluor 488 secondary antibodies were used for detection 
(green). Sections were also labeled with Alexa-fluor- alpha-bungarotoxin (α-BTX; Invitrogen, 
Eugene, OR; red) [43]. NMJs that exhibited an overlap of red and green were considered 
innervated, while those that exhibited only α-BTX expression were considered denervated. The 
percentage of innervated NMJs was determined by counting at least 600 NMJs in each 
treatment group using previously established counting criteria [36]. 
3.3.13 Western blots. 
To determine that nanozyme administered via intraperitoneal injection could be 
detected in muscle five microliters (5 kU/kg, 15 kU/kg or 25 kU/kg doses) were injected 
unilaterally into the tibialis anterior (TA). After one hour, animals were deeply anesthetized, 
decapitated and the TA was dissected and frozen in liquid nitrogen and stored at -80C. 
Additional SOD1 mice were treated intraperitoneally with 100ul of nanozyme (5 kU/kg, 15 
kU/kg or 25 kU/kg doses) for five consecutive days, sacrificed and the TA was removed and 
frozen in liquid nitrogen. Protein isolation from the TAs was performed using RIPA buffer and 
sonication. 50 ug of protein from each sample were resolved on a 10% SDS-PAGE before 
transferring onto an Immobilon-FL PVDF membrane (IPFL00010 Millipore, Billerica MA). 
The membrane was then blocked in an Odyssey Blocking buffer (Li-Cor, Lincoln, NE) that 
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was diluted 1:1 with PBS, for one hour at RT followed by an overnight incubation at 4C with 
an anti-Polyethylene glycol antibody (PEG-B-47 ab 51257 Abcam, Cambridge MA). The 
membrane was washed in PBST the next day before being incubated with a Li-Cor IRDye 
680RD secondary antibody (Li-Cor, Lincoln, NE) for one hour at RT. The membranes were 
washed in PBST and rinsed in PBS before being scanned on an Odyssey Infrared Imaging 
System (Li-Cor, Lincoln, NE), and quantified on ImageJ using densitometry analysis. 
3.3.14 Statistical analysis.  
Statistical analysis was done using Prism 5.0 software (GraphPad, CA). Statistical 
differences between treatment groups were determined using unpaired Student's t-test for 
groups of two and one-way ANOVA followed by Tukey's multiple comparison test for groups 
of three and above. A minimum P-value of 0.05 was estimated as the significance level. Results 
of all experiments are presented as mean ± (SEM) if not specified. The number of animals used 
in the ALS study was based on experimental requirements for analysis and were chosen for a 
two-sided analysis of population means with an acceptable probability of a Type I error (p-
value) of 0.05 or less and a probability of a Type II error of 0.05 or less. Statistical significance 
occurred when power was determined to be 80% or better and the p value was equal to or less 
than 0.05. In all animal studies, experimenters were blinded to treatment groups until all results 
were obtained and statistical analysis completed. 
3.4 Results 
3.4.1 Analysis of nanozyme formation by SDS-PAGE.  
Formation of DET-based nanozyme was confirmed by monitoring its migration pattern 
on a denatured polyacrylamide gel at different stages of the synthesis. SDS-PAGE for native 
SOD1 typically shows two bands representing monomer (16 kDa) and dimer (32 kDa, Figure 
3.1 B, lane 1). By simply mixing the enzyme with PEG-DET copolymer, the dimer band 
disappeared while the monomer band became more intense (lane 2). After cross-linking of the 
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nanozyme with DTSSP, most staining was observed near the wells, which is consistent with 
formation of a larger and electrically neutral cross-linked nanozyme that is not disrupted by 
SDS [32, 63] (Figure 3.1 B, lane 3). In addition, SOD1 monomer band was diminished, and a 
new band appeared at a position slightly lower than the SOD1 dimer. This band could be either 
DTSSP crosslinked PEG-DET or a conjugate of SOD1 monomer and PEG-DET, or a mixture 
of both, since the molecular weight of SOD1 monomer (16 kDa) is very similar to that of PEG-
DET (15 kDa). After purification, the relative intensity of both these bands decreased (Figure 
3.1 B, lane 4). Under the reducing condition where all samples were incubated with 20mM 
DTT for 30 minutes at 37 oC before loading onto the gel, all samples were reduced to the SOD1 
monomer state. Protein smears characteristic of PEG-SDS interactions [193] were observed in 
the cross-linked nanozyme samples (Figure 3.1 B, lanes 3 and 4), suggesting effective and 
complete reduction of nanozyme, which released polymer-protein conjugates as well as the 
native protein. 
The above-described phenomenon of the disappearance of the SOD1 dimer band after 
mixing the enzyme with PEG-DET copolymer was intriguing (Figure 3.1 B, lane 2). Since the 
dimer was not observed in any of the samples at the reducing conditions, we hypothesized that 
in the case of the native SOD1 the cross-linked dimer was formed upon heating of the sample 
before electrophoresis due to oxidation and conjugation of the SOD1 free thiol groups. Indeed, 
bovine SOD1 is a homodimer stabilized by hydrophobic interactions, and the only free thiol 
group on the monomer happened to be located at the interface between the two monomers 
[194] (Cysteine 6, Figure 3.1 D). To examine the role of the thiol groups in the cross-linking 
of SOD1, we conjugated a fluorescent dye (Dylight 594) to native SOD1 cysteine via the 
maleimide chemistry to block the free thiol groups, and ran the samples on SDS-PAGE under 
non-reducing conditions. The conjugation was validated by the appearance of the fluorescent 
signal in the same location as the SOD1 monomer band (Figure 3.1 C, lane 6). After this 
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modification, the dimer band of native SOD1 again disappeared, which suggests that the thiol 
groups of SOD1 play a critical role in the formation of the cross-linked dimer. For some reason 
(e.g. steric hindrance or allosteric effects) such cross-linking did not take place when SOD1 
was incorporated into the polyion complex with PEG-DET. 
3.4.2 Characterization of DET-based nanozyme 
We used several physicochemical techniques to analyze purified samples of DET-based 
nanozyme in aqueous dispersion. The DLS Z-average hydrodynamic radius (Rh), PDI, and ζ-
potential of DET-based nanozyme are presented in Table 3.1 in comparison with the 
parameters of the PLL-based nanozyme while the representative particle size distribution is 
shown in Figure 3.3 A. 
These two nanozyme formulations appeared to be very similar in terms of their sizes 
and charge. The catalytic activity of these two nanozymes measured by pyrogallol assay was 
also very similar (45% vs. 51% of the activity of native SOD1). The further detailed analysis 
of the DET-based nanozyme was carried out by SEC-MALS. Using this method we determined 
the Z-average radius of gyration (Rg) and molar mass (Mw) of the nanozyme to be 13.0 (±8.0%) 
nm, and 2.8 x 106 (±0.4%) Da, respectively (Figure 3.3 B). The structure-sensitive parameter 
(Rg/Rh) has a value of 0.783, which is consistent with the theoretical value (0.775) for spherical 
particles [195]. The spherical morphology of DET-based nanozyme was further confirmed by 
AFM in the amplitude mode (Figure 3.3 C). DET-based nanozymes were well dispersed on 
the mica and displayed uniform size and spherical shape, consistent with the theoretical 
calculations from SEC-MALS data. The particle radius was plotted on a histogram (Figure 3.3 
D), and the data approximately followed Gaussian distribution, with a mean of 13.6 nm, and a 
SD of 3.1 nm. This value is consistent with its Rg and Rh measurements from SEC-MALS and 
DLS. 
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3.4.3 Cytotoxicity of nanozyme 
Cytotoxicities of nanozymes and polymers used for the nanozyme synthesis were 
evaluated in 2 different cell lines by MTS assay after 24 h of incubation (Figure 3.4 A, B). The 
hCMEC/D3 cell line is an immortalized human cerebral microvascular endothelial cell line that 
is commonly used to model the blood-brain barrier (BBB) in vitro. The NSC-34 cell line is a 
motor neuron-like cell line produced by fusion of a neuroblastoma cell line with mouse motor 
neuron-enriched primary spinal cord cells. DET-based nanozyme was well-tolerated by both 
cell lines with cell viabilities around 86 ± 1.6% (hCMEC/D3) and 78 ± 1.6% (NSC-34) even 
at SOD1 concentrations as high as 0.5 mg/mL. These values are very similar to those measured 
for native SOD1 alone (84 ± 2.6% in hCMEC/D3 cells, and 84 ± 1.9% in NSC-34 cells). In 
contrast, PLL-based nanozyme was more cytotoxic at the same concentration resulting in lower 
cell viabilities of 51 ± 2.6% (hCMEC/D3) and 51 ± 2.9% (NSC-34), respectively.  
Similar results were observed when we compared the cytotoxicity of PEG-PLL and 
PEG-DET free polymers by incubating them at different concentrations in the absence of 
SOD1. More drastic differences in viability of both cell lines were observed after incubation 
with the two polymers (Figure 3.4 C, D). In the hCMEC/D3 cell line, PEG-DET had an IC50 
value of 104.9 µM, and was about 3227% less toxic than PEG-PLL, whose IC50 value was 
3.251 µM. In the NSC-34 cell line, both polymers were less tolerated than in the hCMEC/D3 
cell line, with IC50 values of 14.68 µM (PEG-DET) and 2.027 µM (PEG-PLL), respectively. 
3.4.4 Biodistribution and Pharmacokinetics 
Biodistribution profile of the two nanozymes was compared in healthy C57BL/6 mice 
1 hour after IV administration (Figure 3.5 A). As reported and extensively discussed in our 
previous work [12], PLL-based nanozyme formulation could significantly reduce kidney 
accumulation of native SOD1, and increase its uptake in almost all other organs, most notably 
liver (13.6% of ID) and spleen (30.7% of ID) due to its high cationic charge density. In the 
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current work, DET-based nanozyme showed remarkably lower uptake in these two organs 
(4.7% of ID in the liver, and 6.6% of ID in the spleen) compared to PLL-based nanozyme, 
although the uptake is still significantly higher than native SOD1.  
In organs other than liver and spleen, no statistically significant difference in uptake 
was observed between the two formulations. In the serum clearance analysis, both nanozyme 
formulations demonstrated statistically significant linear relationships between log(%Inj/mL) 
and time, indicating first-order kinetics in their early phases of clearance (Figure 3.5 B). The 
serum half-life (t1/2) for DET-based nanozyme was 28.4 min (R
2 = 0.6804, P =0.0136), 
comparable but shorter than that of PLL-based nanozyme (33.8 min), and longer than native 
SOD1 (10.3 min). 
In addition to the biodistribution study where the total drug amount was measured at a 
fixed time point after injection, we also performed multiple time linear regression analysis, 
which adopts a graphical approach and evaluates the unidirectional influx rate (Ki) into 
different organs over a period of time. This experiment was performed in selected organs of 
interest (liver, spleen, and kidney) during 1-70 min of exposure time after an IV bolus injection 
of 125I-SOD1 samples (Figure 3.5 C-E). The unidirectional influx rates (Ki) were calculated as 
described in section 3.3.7 , and summarized in Table 3.2. Not surprisingly, the Ki values of 
125I-labeled SOD1 nanozymes were highly consistent with their biodistribution pattern. Both 
nanozymes entered the kidney at an influx rate about 70% slower than that of native SOD1. 
PLL-nanozyme showed the fastest influx rates into the liver and spleen while DET-based 
nanozyme had much slower rates at only 23.2% and 20.6% (respectively) relative to PLL-based 
nanozymes. Native SOD1 was mainly sequestered in the kidney while almost negligible uptake 
was noted in the liver and spleen.   
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3.4.5 Infarct volume analysis in mouse MCAO model of ischemic stroke 
In vivo therapeutic efficacy of DET-based nanozyme was tested in a well-established 
mouse MCAO model of ischemic stroke. The DET-based nanozyme treatment reduced the 
infarct size in this model of stroke. Specifically, in the nanozyme treatment group the volumes 
of infarct as determined by TTC staining in the three different brain regions analyzed (cortex: 
32.0±6.9%; caudoputamen: 30.7±8.9%; hemisphere: 25.6±6.4%) were significantly smaller 
compared to those in animals injected with saline or native SOD1 (Figure 3.6). This protection 
effect is comparable to that previously reported by us using PLL-based nanozyme in the same 
animal model [12]. 
3.4.6 Treatment of the mutant SOD1G93A mouse model of ALS 
As reviewed in our recent paper, initial muscle denervation occurs in the TA muscle 
(fast fatigable and fatigue resistant fibers) between postnatal day (P) 14 and P30, while little 
denervation occurs in soleus muscle (slow and fatigue resistant fibers) even later in disease 
[196, 197].  In this study SOD1 mice were treated beginning at P30 to determine if the DET-
based nanozyme could promote NMJ innervation. Two groups of animals were initially treated 
with 5 or 15 kU/kg native enzyme or nanozyme. No significant differences in NMJ innervation 
were detected in any treatment group (Figure 3.7 C; 15 kU/kg data not shown). Given the lack 
of positive effect, we next determined if the nanozyme reached muscle and therefore had access 
to the NMJ, muscles from treated animals (5, 15 or 25 kU/kg) were collected and western blot 
analysis performed to detect the DET-based nanozyme. Nanozyme was not detected in the TA 
muscles of animals treated at the 5 or 15 kU/kg doses (not shown); however, nanozyme was 
readily detected at the 25 kU/kg dose. When animals were treated with the 25 kU/kg dose, there 
was a slight increase in NMJ innervation in the native enzyme and nanozyme groups; however, 
this was not significantly different from the saline treated control group (Figure 3.7 D). 
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3.5 Discussion 
In this paper we reported a new SOD1 nanozyme formulation based on a cationic 
copolymer PEG-DET, which had received considerable attention over the past decade as an 
excellent gene delivery carrier due to its low toxicity and high transfection efficiency. The 
preparation of this DET-based nanozyme was monitored and characterized first by SDS-PAGE 
experiment, where samples collected from different stages of preparation were analyzed by 
denaturing gel electrophoresis similar to our previous report on PLL-based nanozyme [32, 63], 
and the migration patterns were consistent between the two nanozyme formulations. Most of 
the crosslinked nanozymes were unable to migrate in the gel, consistent with the expected size 
increase and charge neutralization after formulation. Interestingly, when we loaded a simple 
physical mixture of SOD1 and PEG-DET on the gel (Figure 3.1 B, lane 2), the SOD1 dimer 
band at 32 kDa disappeared and the intensity of the monomer band increased notably. 
Intrigued, we further investigated this phenomenon. Native SOD1 dimer is stabilized 
by 4 hydrogen bonds and extensive hydrophobic interactions at the interface between its two 
monomers [198]. Incubation with 1% SDS is enough to interrupt these interactions, and 
converts all the protein to its monomer form after native gel electrophoresis [199]. In our SDS-
PAGE experiments, the SOD1 dimer was probably formed due to partial oxidation during 
heating the sample to 95 °C which led to disulfide bond formation between the free thiol groups 
of Cys 6 (Figure 3.1 D, the only free thiol group on the bovine SOD1 monomer [200]) residues 
on each monomer, because the dimer band completely disappeared in the DTT reduced 
samples. We proved this hypothesis by reacting the Cys 6 group with a maleimide-Dylight 594 
fluorophore. After electrophoresis, the fluorescence was readily detectable on the 16 kDa 
monomer band after the thiol-maleimide conjugation reaction, and the dimer band again 
disappeared (Figure 3.1 C).  
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Our data indicates an interaction between PEG-DET and native SOD1 that inhibits the 
formation of disulfide bonds between free cysteine groups located in the hydrophobic interface 
of the monomers. This kind of disulfide bond formation has been reported to be involved in 
the oxidation pathways of SOD1 protein in vitro and in vivo [201-203], and blocking the free 
thiol group on SOD1 has been shown to confer nearly complete protection against peroxide 
induced oxidation [201]. Although non-cross-linked nanozyme is not an ideal formulation for 
SOD1 delivery due to its instability in in vivo conditions [32], its oxidation-inhibiting effect 
can be potentially utilized to develop a simple way for SOD1 storage without the need to 
chemically block its free thiol groups. To our knowledge, this work is the first report 
demonstrating inhibition of SOD1 oxidation through a non-covalent formulation approach. 
The hydrodynamic size, ζ-potential, and SOD1 catalytic activity of DET-based 
nanozyme were very similar to PLL-based nanozyme (Table 3.1). Moreover, dynamic/static 
light scattering and atomic force microscopy data confirmed the shape of DET-based 
nanozyme to be spherical, again same as PLL-based nanozyme [32]. Structural density (ρ) of 
DET-based nanozyme can be calculated using the equation ρ = 3Mw / (4πNARg3), where Mw 
denotes molar mass, NA denotes the Avogadro constant, and Rg denotes the radius of gyration. 
Based on our data obtained from the SEC-MALS experiment, DET-based nanozyme had a 
structural density (ρ) value of 0.597g/mL, which is about 40% of the reported average density 
of compact proteins (1.47g/mL) [204]. This value is consistent with the “cage”-like hollow 
structure of the nanozyme formulation [32]. While it is reasonably compact after chemical 
cross-linking, there is still a large aqueous environment (~60%) inside the core, which is 
available for superoxide anions to freely access the SOD1 active sites and undergo dismutation, 
as well as for the reaction products (hydrogen peroxide and oxygen) to escape from them . 
This structure allows the SOD1 activity to be immediately available without the need 
of being released, which is a major advantage compared to most other nano-formulations of 
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SOD1, and makes this formulation especially useful in scavenging acute ROS. Indeed, in a 
mouse MCAO model of ischemic stroke, DET-based nanozyme significantly reduced the brain 
infarct sizes by more than 50% (Figure 3.6), comparable to our previous reports on PLL-based 
nanozymes [12, 32].  
The major advantage of DET-based nanozyme over PLL-based nanozyme involves the 
unique molecular structure of the DET repeating units which makes its toxicity much lower 
than PLL as described earlier. Consistent with theoretical speculations, PEG-DET appeared to 
be remarkably less toxic than PEG-PLL in both cell lines tested. The hCMEC/D3 cell line 
appeared to be more resistant to cationic toxicity than NSC-34 cells, which can be explained 
by the hierarchy of susceptibility to injures among brain cells (i.e. neurons are generally more 
vulnerable than endothelial cells) [205].  
Interestingly, the dose-response curve for DET-based nanozyme was very similar to 
native SOD1, reflecting toxicity primarily caused by SOD1 overdose [206]. On the contrary, 
PLL-based nanozyme started to exert the same level of toxicity at lower doses, and was 2 to 3-
fold more toxic than native SOD1 at the highest dose tested. Indeed, most primary amine 
groups on the polymers were cross-linked with stoichiometric DTSSP in both nanozyme 
formulations. However, considering the reaction efficiency and possible reaction between 
DTSSP and SOD1, DTSSP cannot conjugate 100% of the free amine groups on the polymers. 
Therefore, the cytotoxicity at high PLL-based nanozyme doses likely involved free lysine 
groups. The lack of cytotoxicity in DET-based nanozyme can be explained by the two-step 
protonation behavior of the free DET unit with a distinctive gauche-anti conformational 
transition, which can effectively reduce its charge density at physiological pH, and improve its 
cyto-compatibility [89]. This two-step protonation behavior of PEG-DET is further 
characterized by potentiometric titration (Figure 3.2). The protonation degree (α)/pH curve 
calculated from the titration curves indicates ~40% increase in α value through the pH drop 
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from 7.4 to 5.0. In contrast, PEG-PLL showed one step protonation with very little change in 
α value over all pH values below 9. Apparent pKa values of PEG-DET were determined to be 
9.9 (α =0.25) and 6.1 (α =0.75), respectively, consistent with previous reports on this polymer 
[89].  
The distinct protonation behavior of the two polymers also resulted in remarkable 
differences in biodistribution and pharmacokinetics between DET and PLL-based nanozymes. 
Nanoparticles are well known for extensive accumulation in the liver and spleen after IV 
injection, primarily due to sequestration by the MPS [207]. This process is mediated by 
macrophages and phagocytic cells which can recognize opsonins (serum proteins) adsorbed 
onto nanoparticles [208]. In our study, the MPS accumulation (13.6% in the liver, and 30.7% 
in the spleen) of PLL-based nanozyme at 1h after injection appears to be very high for a 
PEGylated nanoparticle of its size (~40nm). Shah et al. reported PEGylated 30nm gold 
nanoparticles to have 30% accumulation in the liver and 60% accumulation in the spleen at 24 
hours after IV injection. However, only 7% and 6% (respectively) were detected at the 1h time 
point [209], which is more consistent with DET-based nanozyme accumulation in the liver and 
spleen (4.7% and 6.6%). The rapid accumulation of PLL-based nanozyme into the MPS organs 
reflects the interaction between free ζ-lysine groups on PLL-based nanozyme with serum 
proteins, which has been shown in our previous work in a thrombus incorporation assay [12]. 
To further understand the difference, we also looked at the thrombus incorporation level of 
DET-based nanozyme (Figure 3.8). The fraction of DET-based nanozyme incorporated into 
the thrombus compartment was determined to be 5.9 ± 0.5%. This value is about 30% higher 
than those of BSA and native SOD1, but significantly lower than PLL-based 
nanozyme (8.2 ± 0.2%). This result is understandable considering the charge-shielding effect 
of free ethylenediamine groups on the PEG-DET polymer as we mentioned earlier. While free 
lysine groups in PLL-based nanozyme quickly activates opsonization and MPS sequestration, 
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the free ethylenediamine groups in DET-based nanozyme masks its charge by the gauche 
conformation and therefore effectively slowed down MPS sequestration. 
Interestingly, the ability to be incorporated into thrombus happened to be an important 
feature for PLL based-nanozyme to passively target to injured blood vessels after stroke and 
exert therapeutic effects [12]. To see whether the DET-based nanozyme also displays the 
therapeutic potential in stroke, we tested this formulation in the same mouse MCAO model of 
ischemic stroke. To our surprise, the DET-based nanozyme formulation was almost as effective 
as PLL-based nanozyme in terms of infarct volume reduction. On the contrary, while native 
SOD1 also showed about 4% thrombus incorporation, it almost had no therapeutic effect as 
compared to saline. This result signifies the importance of formulation to protect the 
therapeutic protein. When native SOD1 was most likely deactivated after being chemically 
crosslinked into the thrombus, nanozyme formulations of SOD1 were able to remain active and 
rescued the injured blood vessels. 
3.6 Conclusion 
We have developed a new SOD1 nanozyme formulation by replacing PLL with the 
DET polymer in its composition. Compared to PLL-based nanozyme, the new formulation has 
similar morphology and colloidal properties, as well as anti-oxidant activity in vitro and in 
vivo. Moreover, this formulation proved to be significantly less toxic to endothelial cells and 
neurons, and accumulates less into the liver and spleen. While being effective in stroke, this 
formulation did not show significant prevention against NMJ denervation in the ALS model, 
suggesting the need for further engineering to better target the brain and spinal cord. 
3.7 Future directions 
With the exact cause and the progression pathways of ALS still not fully understood, 
the choice of protecting the peripheral vs. central nervous system appears to be especially 
complicated. The lack of therapeutic efficacy of DET-based nanozyme in the ALS model 
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countered our initial hypothesis, nevertheless these results offer an insight for further 
development of anti-oxidant based therapies for ALS management. We confirmed that the 
DET-based nanozyme achieved detectable levels in the tibialis anterior muscle, while the dose 
or dosing frequency was likely not optimized well enough for this therapy to be effective. 
Alternately, delivery of the nanozyme to the periphery (muscle, NMJ and axon) alone may not 
be sufficient to delay or prevent NMJ denervation that is a hallmark of the disease progression. 
Our biodistribution data indicate that the nanozyme does not achieve high concentrations in the 
brain (and presumably spinal cord) suggesting insufficient delivery across the BBB. As such, 
the nanozyme may not reach the motor neuron cell bodies or non-neuronal cells affected in 
ALS.  
Could the administration route of nanozyme be a reason to explain its lack of efficacy 
in the ALS model? It is possible. In the introduction, we mentioned that the IP route was chosen 
with considerations on patient compliance from a translational perspective, as compared with 
IV administration. However, with this injection route we would expect to lose a considerable 
portion of the drug before it reaches the muscle tissues although we were able to detect their 
existence by western blot. If we performed direct intramuscular injection, we could be able to 
deliver a much higher dose to the muscle and see a better therapeutic response with that 
approach. Its down side would possibly be uneven distribution of nanozyme in the body, and 
the site of muscle tissue collection will need to be carefully selected and consistent throughout 
the study. 
Future studies will test if delivery specifically to the central nervous system is effective 
in decreasing muscle denervation.  This can be achieved by surface modification of the 
nanozyme formulation so that they can actively target to transporter or receptors on the BBB 
which can hopefully facilitate their trans-BBB delivery. 
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Figure 3.1 SDS-PAGE analysis of DET-based nanozyme. 
A. Schematic representation of the synthesis of DET-based nanozyme (polyion complexation 
followed by chemical cross-linking using DTSSP) and the two-step protonation behavior of 
the DET polymer; B. DET-based nanozyme samples were collected at different stages of 
formulation (1. Native SOD1, 2. Physical mixture of SOD1 with PEG-DET copolymer, 3. 
Crosslinked non-purified DET-based nanozyme, 4. Purified DET-based nanozyme), and 
incubated with either Laemmli loading buffer (-DTT) or laemmli loading buffer with 20mM 
DTT (+DTT) before SDS-PAGE; C. The free thiol group on Cysteine 6 of SOD1 was reacted 
with Dylight 594 using the maleimide chemistry, and the samples before and after conjugation 
(5. Native SOD1, 6. SOD1 – Dylight 594 conjugation) was compared on a SDS-PAGE gel; D. 
Illustration of the position of Cysteine 6 on the bovine SOD1 molecule, drawn with the PyMOL 
software package (http://www.pymol.org/). The red balls represent Cysteine 6 and the blue and 
green loops each represents a SOD1 monomer. 
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Figure 3.2 Protonation behavior of PEG-DET and PEG-PLL. 
Change in protonation degree (α) with pH (α/pH curve) (150 mM NaCl, 37 °C). 
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Figure 3.3 Characterization of DET-based nanozyme. 
Crosslinked and purified nanozyme made from PEG-DET polymer and native SOD1 was 
characterized with a combination of different techniques. A. Representative graph of 
hydrodynamic size measurements for DET-based nanozyme and native SOD1 by DLS. The 
size distribution by intensity was plotted in the range of 0-70nm. B. A typical RI peak from 
SEC-MALS chromatogram of DET-based nanozyme together with the molar mass and radius 
of gyration (Rg) vs. retention time throughout the peak. C. AFM image of DET-based 
nanozyme in amplitude mode at ambient conditions. D. Histogram of DET size distribution (n 
= 540) as measured on the AFM image shown in C.  
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Figure 3.4 In vitro cytotoxicity to endothelial and neuronal cells after 24 h incubation. 
Different concentrations of native SOD1, PLL-based nanozyme, DET-based nanozyme, PEG-
DET, and PEG-PLL were diluted in serum-free cell culture medium, and added to cultured 
hCMEC/D3 (A, C) and NSC-34 (B, D) cells (n = 4, each). Twenty-four hours later, cell 
viability was assessed by MTS assay. Values are shown as mean ± SEM. (Some error bars are 
smaller than the symbol and thus not seen.) The extra color-coded X-axes underneath C and D 
represent the expected concentration of SOD1 when the respective amount of each polymer 
were used to synthesis SOD1 nanozymes. 
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Figure 3.5 Polymer properties affecting biodistribution and influx rates of nanozyme. 
A. Biodistribution of 125I-labeled native SOD1 (n = 7), PLL-based nanozyme (n = 8), and DET-
based nanozyme (n=8) 1h after IV administration in C57BL/6 mice. Symbols above nanozyme 
groups denote significance levels compared to the native SOD1 group. Results represent 
percentage of ID per gram of tissue (ID%/g). B. Serum clearance profiles of 125I-SOD1 in 
different formulations after IV injection plotted and analyzed by linear regression fitting. DET-
based nanozyme prolonged the circulation half-life (t1/2) of native SOD1 from 10.3 min to 28.4 
min, comparable to that of PLL-based nanozyme (33.8 min). C-E. Influx of 125I-SOD1 into 
kidney, liver, and spleen over the exposure time of 1-70 min after IV injection. The influx rates 
confirmed the same patterns as we observed in the biodistribution experiment.   
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Figure 3.6 DET-based nanozyme reduced infarct volumes in the mouse MCAO model of 
ischemic stroke. 
At the onset of reperfusion, 10,000 U/kg of native SOD1 (n = 8), DET-based nanozyme 
(n = 8), or equal volumes of saline (n = 7) was injected through the right jugular vein of the 
mice under anesthesia. Twenty-four hours after reperfusion, mice were euthanized and their 
brains were sectioned and stained using TTC solution. A. Bar graph showing infarct volume 
reduction. Infarction (% contralateral) was quantified as described in section 3.3.9 . Data were 
analyzed using one-way ANOVA with Tukey's post-hoc test and presented as mean ± SEM. 
Statistical significance is defined as P < 0.05, and indicated by * (P < 0.05), ** (P < 0.01), or 
**** (P < 0.0001). B. Illustration of brain regions indicated in A.  
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Figure 3.7 DET-based nanozyme was not effective against NMJ denervation in SOD1G93A 
mice. 
A. To determine if the nanozyme accumulated in muscle western blot analysis was performed 
to detect PEG. One wild-type (lane 1) and SOD1 (lane 2) mouse was intramuscularly injected 
with nanozyme (5ul) and TA collected after one hour. Additionally, two SOD1 mice (lanes 3, 
4) were treated with 25 kU/kg nanozyme via intraperitoneal injection for 5 days and TA’s 
collected after the 5th IP treatment. PEG-nanozyme was detected in TA of all mice treated with 
25 kU/kg nanozyme either with intramuscular or IP injection. No PEG-labeled nanozyme was 
detected at the 5 or 15 kU/kg doses. B. Innervation of neuromuscular junctions (NMJs) was 
determined with immunohistochemistry where presynaptic terminals were identified with 
antibodies to vesicular acetylcholine transporter (VAChT) and axons identified with an 
antibody to neurofilament (NF). Both antibodies were detected with Alexa Fluor 488 
conjugated secondary antibodies (green). Postsynaptic acetylcholine receptors were identified 
with Alexa Fluor 555 conjugated alpha-bungarotoxin (α-BTx; red). NMJs where no co-label 
for VAChT and only α-BTx were considered denervated (arrow head). Those NMJs with 
overlap, even if partial were counted as innervated (arrow).  C-D. SOD1G93A mice were treated 
at a SOD1 dose of either 5 kU/kg (n = 5-7) or 25kU/kg (n=13-16) via IP injection every other 
day starting on P30 through P75 and NMJ innervation were determined in the tibialis anterior 
(TA) and soleus muscles. There was no difference in the extent of NMJ innervation among the 
treatment groups in either tissue. Results are expressed as mean ± SEM.  
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Figure 3.8 Thrombus incorporation in mouse plasma. 
DET-based nanozyme showed higher level of thrombus incorporation than native SOD1, but 
lower than that of PLL-based nanozyme. Red, blue and green color represent native SOD1, 
PLL-based nanozyme, and DET-based nanozyme, respectively in all figures. Data were 
presented as mean ± SEM. Statistical significance was determined by unpaired Student's t-test 
(indicated as the following: n.s., not significant; *, P < 0.05; **, P < 0.01; ****, P < 0.0001, #, 
P<0.0001 compared with all other groups). 
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Table 3.1 Characterization of native SOD1 and different formulations of nanozymes.a b 
Sample Rh, 
(nm) 
PDI ζ-potential, 
(mV) 
Enzyme activity, 
(% of initial)c 
Native SOD1 2.8 0.60 -1.3 100 
PLL-based nanozyme [32] 16.9 0.03 0.6 45 
DET-based nanozyme 16.6 0.09 0.4 51 
 
a Nanozymes were prepared at polycation to SOD1 protein charge ratio Z+/− = 2.  , chemically 
crosslinked and purified as described in section 3.3.3 . Rh, PDI and ζ-potential were measured 
in 10 mM HEPES, pH=7.4. Catalytic activity of SOD1 was measured by pyrogallol 
autoxidation assay and normalized to Cu2+ and Zn2+ concentrations determined by ICP-MS. 
b Rh, PDI, ζ-potential data are representative of > 5 independent experiments. Measurement 
error was typically < 10%. 
c Enzyme activity data is representative of > 5 independent experiments. Measurement error 
was typically < 5%. 
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Table 3.2 Influx rates (Ki, µl/g-min) of different SOD1 formulations into brain, kidney, 
liver, and spleen during 1-70 min of exposure time after an IV bolus of 125I-SOD1. 
Formulation Kidney Liver Spleen 
Native SOD1 59±7.0 0.10±0.17 0.17±0.05 
PLL-based nanozyme 18±2.0 1.3±0.2 6.7±1.1 
DET-based nanozyme 21±7.7 0.29±0.13 1.4±0.2 
Fa 0.16 12 17 
Pb 0.70 0.0069 0.0025 
a F denotes the results of F-tests assuming the null hypothesis that PLL-based nanozyme and 
the DET-based nanozyme have identical Ki values. 
b P denotes the P-values associated with the F-values indicated on the row above. 
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CHAPTER 4  BLOCK IONOMER COMPLEX NANOFORMULATION STABLIZES 
BRAIN DERIVED NEUROTROPHIC FACTOR AND INCREASES ITS DELIVERY 
TO THE BRAIN AFTER INTRANASAL ADMINISTRATION4 
4.1 Summary 
Delivery of protein therapeutics to the brain has proven to be an intractable obstacle to 
effective treatments of neurological disorders. For example, brain derived neurotrophic factor 
(BDNF) has been identified as a possible therapeutic for a variety of neurological diseases. 
However, its delivery is hampered by poor serum stability and brain-to-blood efflux. Here, we 
report a simple block ionomer complex (BIC) formulation composed of a biocompatible 
polymer, poly(ethylene glycol)-b-poly(L-glutamic acid) (PEG-PLE), that hosts the BDNF 
molecule in a nanoscale complex, termed here Nano-BDNF. We show that Nano-BDNF forms 
as monodisperse, spherical particles with a core-shell structure. Molecular dynamics (MD) 
simulations suggest that binding between BDNF and PEG-PLE is mediated through 
electrostatic coupling as well as hydrogen bonding. The formation of BIC stabilizes BDNF and 
protects it from interacting with nonspecific binding partners while allowing it to associate with 
the BDNF receptor, tropomyosin receptor kinase B (TrkB). Nano-BDNF compared to BDNF 
is retained by brain after INB administration and has increased accumulation throughout the 
brain with targeting to the hippocampus and hypothalamus.  
4.2 Introduction 
Brain derived neurotrophic factor (BDNF) promotes neuron survival and long term 
potentiation, thus implicating it as a prime therapeutic candidate for a host of neurological 
disorders [210-215]. However, despite an endogenous transporter for BDNF across the BBB, 
                                                 
4 This chapter previously appeared as a manuscript soon to be submitted. 
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its serum half-life is short [216-218]. Consequently, BDNF’s efficacy for the treatment of CNS 
diseases after peripheral administration is low [219-222]. To overcome this problem, intranasal 
to brain (INB) administration has emerged as a promising route for delivering peptides and 
proteins to the CNS [223-228] . Briefly, the candidate drug is delivered high into the nasal 
cavity to the level of the olfactory bulb/cribriform plate where it can travel up along the 
olfactory and trigeminal nerves to reach the CNS without encountering the BBB [228, 229]. A 
recent report demonstrated efficacy in delivering intranasal insulin to the brains of Alzheimer’s 
patients [230]. By bypassing the BBB and permitting only minimal exposure to the peripheral 
organs, INB administration can overcome the primary obstacles preventing BDNF delivery. 
Additional advantages of this approach include non-invasiveness and rapid onset of 
effects[228]. 
In its native, unmodified state, BDNF is not an immediately attractive candidate for 
intranasal delivery. In Alcala-Barraza et al., BDNF was delivered via INB administration, 
pharmacokinetic studies then demonstrated that BDNF was primarily localized in the olfactory 
bulb and trigeminal nerve with little appearance in more therapeutically relevant regions like 
the cortex or hippocampus. [231].  Poor penetration to the relevant portions of the brain has 
been attributed to entrapment and subsequent degradation of BDNF within the nasal mucosa 
[232]. Indeed, BDNF features cationic surface charges and extensive binding to a variety of 
polysaccharides [233, 234], inhibiting penetration through the negatively charged and sialic-
acid-rich nasal mucosa [235]. 
Protein PEGylation, either through direct modification of the protein with a 
poly(ethylene-glycol) (PEG) chain or encapsulation in a nanoparticle with a PEG exterior, has 
been reported to increase nasal absorption [236, 237]. Unfortunately, PEGylation [238-241] 
can also sterically hinder the binding of cargo proteins with their receptors. In this particular 
context, BDNF must be released in a functionally active conformation to bind TrkB. Thus, an 
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ideal delivery vehicle should not only protect BDNF from mucosal interactions, but also release 
it in the native conformation and present minimum hindrance to interaction with TrkB. 
Here, we present a block ionomer complex (BIC) formulation of PEG-PLE and BDNF 
that self-assembles in an isotonic solution at proper charge ratios. PEG-PLE, an anionic 
biocompatible polymer, interacts with the highly positively charged surface of BDNF while 
simultaneously constructing a PEG shell that protects BDNF from interactions with the nasal 
mucosa. This non-covalent assembly allows release of the native BDNF molecule to TrkB 
while protecting BDNF from non-specific interactions. Indeed, Nano-BDNF maintains activity 
before and after formulation in an NIH 3T3 cell line stably transfected with human TrkB. 
Furthermore, we demonstrate effective INB administration to the brain in CD-1 mice.  
4.3 Materials and methods 
4.3.1 Chemicals. 
Methoxy-poly(ethylene glycol)-block-poly(L-glutamic acid sodium salt) (PEG-PLE) 
was purchased from Alamanda Polymers™ (Huntsville, AL). Its molecular mass determined 
by gel permeation chromatography was 13 KDa, and polydispersity index was 1.00-1.20; the 
PEG molecular mass was 4.5 - 5.5 KDa and the degree of polymerization of the PLE block 
was 45-55. Recombinant human BDNF was purchased from PeproTech (Rocky Hill, NJ). 
Human Serum Albumin (HSA), Bovine Serum Albumin (BSA) powder, and SuperSignal™ 
West Pico Chemiluminescent Substrate was from Thermo Fisher (Waltham, MA). Lactate 
buffered Ringer’s solution (LR), uranyl acetate, Protease&phosphatase Inhibitor Cocktail, and 
agarose tablet were purchased from Fisher Scientific. Chloramine T, RIPA Buffer, urethane, 
and IgG from human serum were purchased from Sigma-Aldrich (St. Louis, MO); Mini-
PROTEAN® TGX™ Precast Protein Gels, bio-safe commassie stain solution, sample loading 
and running buffers for electrophoresis were purchased from Bio-rad (Hercules, CA). 
Recombinant human TrkB Fc chimera protein (TrkB-Fc) was purchased from R&D systems 
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(Minneapolis, MN). Na125I was purchased from PerkinElmer Life Sciences (Boston, MA); 
GlutaMAX™ high glucose Dulbecco's Modified Eagle Medium (DMEM) was purchased from 
Invitrogen (Carlsbad, CA); Anti-Phospho-TrkA (Tyr490)/TrkB (Tyr516) rabbit monoclonal 
antibody (used in 1:1000 dilutions in 5% BSA), Anti-Phospho-p44/42 MAPK (ERK1/2) 
(Thr202/Tyr204) rabbit polyclonal antibody (used in 1:1000 dilutions in 5% BSA), Anti-
p44/42 MAPK (ERK1/2) Rabbit monoclonal Antibody (used in 1:1000 dilutions in 5% non-
fat dry milk), and HRP-conjugated secondary antibodies was purchased Cell Signaling 
Technologies (Beverly, MA); Anti-TrkB rabbit polyclonal antibody (used in 1:2000 dilutions 
in 5% non-fat dry milk) was purchased from Millipore (Bedford, MA); Tris-buffered saline 
(TBS) and Tris-buffered saline with 0.1% Tween 20 (TBST) 10X stock solutions were 
purchased from Boston Bioproducts (Ashland, MA). 
4.3.2 Preparation and characterization of Nano-BDNF 
Nano-BDNF was prepared by mixing BDNF and PEG-PLE in water. Briefly, a 
concentrated PEG-PLE solution was added drop-by-drop to a concentrated BDNF solution 
with gentle vortex at room temperature (RT). The mixture was then diluted with either 10mM 
phosphate buffer (pH = 7.4, PB) or LR to desired concentrations, and gently vortexed for 
another 30 seconds. Complexes were allowed to incubate at RT for 30 min before use in 
experiments. The charge ratio (Z-/+) was calculated as the ratio of the total number of 
carboxylate groups in PEG-PLE (50) to that of arginine and lysine residues in BDNF (44, Based 
on the sequence provided by manufacturer).  
4.3.3 Dynamic light scattering (DLS) 
Nano-BDNF was prepared at various Z ratios and analyzed at 25°C using a Zetasizer 
Nano ZS (Malvern Instruments Ltd., UK) with a scattering angle of 173°.  
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4.3.4 Transmission electron microscopy (TEM) 
Samples were deposited on copper grids coated with thin layers of carbon film and 
dried for 5 minutes. We performed positive staining for 10 seconds with 2% uranyl acetate 
which was then removed using filter paper. All samples were observed under a JEOL 100CX 
II transmission electron microscope set at 100kV. Images were acquired with a digital imaging 
system.  
4.3.5 Atomic force microscopy (AFM) 
Five μL of aqueous dispersion of .01 mg/mL native BDNF or Nano-BDNF (Z-/+ = 10) 
were deposited on the surface of a glass slide and air dried for 15 minutes. We utilized a MFP3D 
system (Asylum Research, Santa Barbara, CA) operated in tapping mode to image the particles.   
4.3.6 Horizontal agarose gel electrophoresis (HAGE) 
Samples containing 2μg of BDNF were electrophoresed through a 0.5% agarose gel at 
80V for 1 hour in Tris/Glycine running buffer, and then stained using Bio-Safe Coomassie 
Stain solution (Bio-Rad, Hercules, CA). We obtained images using the FluorChem™ E series 
imager (ProteinSimple, San Jose, CA) with a 100ms exposure time. The center of mass as 
determined by optical density was obtained using ImageJ (NIH) and defined as the migration 
distance of the sample loaded in that lane. 
4.3.7 Isothermal titration calorimetry (ITC) 
ITC measurements were performed at 25.0 °C by using an auto-ITC200 titration 
calorimeter (Malvern Instruments, MA). The sample cell was loaded with 360 µl of BDNF 
solution (12.5 μM) in 10mM phosphate buffer, pH 7.4 and titrated with1 mM PEG-PLE 
solution in 2 μL aliquots with 3 minute intervals. The first injection was 0.2 μL. We used 
MicroCAl ORIGIN software to determine the site binding model which provided the best fit 
(lowest χ2 value) in order to obtain ΔH0, Kd, and the stoichiometry of association. ΔG0 and ΔS0 
were obtained using the following equations. 
Δ𝐺 = Δ𝐻 − 𝑇Δ𝑆 
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Δ𝐺 = RTln 𝑘 
4.3.8 Molecular dynamic (MD) simulations 
MD simulations were performed in GROMACS 4.6.3 using OPLS-AA force field with 
slightly modified parameters to suit for PEG-PLE simulation as previously reported for 
PEGylated proteins [242]. We extracted the monomer structure (PDB ID 1BND) and 
constructed a dimer by placing to copies in close vicinity and performing a molecular dynamics 
simulation until steady state was achieved [14]. We generated a simulation box around the 
protein and polymers using the editconf module of the GROMACS package. The dimensions 
were selected so that the minimum distance between the protein molecule and the edge of the 
box was 9 Å. Protein models were solvated with the TIP4P water model and, wherever 
necessary, the system was neutralized with Na+ and Cl− ions using the program genbox. All 
MD simulations were performed at constant temperature of 300K and pressure of 1bar for a 
time period of 100 ns. The electrostatic surface potential of BDNF dimer was calculated using 
APBS tool 2.1. The numbers of hydrogen bonds and non-bonding contacts in the trajectory 
were calculated using HBplus program at each step of the trajectory [243] with parameters set 
the same as described by Baker and Hubbard[244] for maximum comparability. . The amino 
acid sequences forming the β-sheets and β-turns on BDNF are identified by PDBsum 
(https://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/pdbsum/GetPage.pl?pdbcode=1bnd).  
4.3.9 Protein thermal shift (PTS) assay 
Samples were prepared by mixing 2 ug of BDNF or equivalent amount of Nano-BDNF 
(Z-/+ = 1, 5, and 10) with the environmentally sensitive dye provided in the Protein Thermal 
ShiftTM Dye Kit (Thermo Fisher). We performed the PTS assay using an Applied Biosystems® 
StepOnePlus™ 7500 Real-Time PCR system, and increased the temperature at a rate of 
0.395°C/min. Melting temperature (Tm) was visualized by plotting the negative first-order 
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derivative of fluorescence over temperature (-dF/dT) versus temperature (T), and determined 
as the local minimum of the curve in the range of 70oC to 95oC. 
4.3.10 Radioactive labelling of BDNF 
 125I-BDNF and 125I-Nano-BDNF were produced using a previously described 
Chloramine T method [12]. Briefly, 5ug of BDNF was mixed with 0.5 mCi Na125I in a final 
volume of 45 µL sodium phosphate buffer (PB, 0.25 M, pH 7.5). Five µL of freshly prepared 
2 µg/ µL chloramine-T solution in PB was then added to the mixture and incubated for 1 minute 
at RT. 125I-BDNF was purified from the mixture with Illustra NAP-5 columns (GE Healthcare, 
Piscataway, NJ), and fractions were collected in Eppendorf tubes pretreated with either 1% 
BSA in lactated Ringer’s solution (1% BSA-LR, for collecting 125I-BDNF) or 0.1% PEG-PLE 
solution in LR (for collecting 125I-Nano-BDNF) to prevent adsorption and the radioactivity of 
each fraction was counted in a PerkinElmer γ-counter. The integrity of 125I-BDNF was 
determined by trichloroacetic acid (TCA) precipitation. Briefly, 1 µL of each fraction was 
added to 0.5 mL of 1% BSA-LR and then precipitated in 0.5 mL of 30 % TCA followed by 
centrifugation at 5400 g for 10 min at 4°C. The radioactivity in the supernatant and pellet were 
counted with γ-counter and the values used to calculate the integrity of 125I-BDNF. Samples 
containing more than 100,000 count per minute (cpm)/µL of radioactivity and precipitate more 
than 95% in TCA were used for animal studies. 
4.3.11 Cell culture and western blot 
NIH 3T3 cells expressing TrkB were cultured in GlutaMAX™ DMEM supplemented 
with calf serum (10%), G418 (100 µg/mL) and Penicillin-Streptomycin (100 U/mL-
100 μg/mL) and were maintained at 37 °C in a humidified CO2 (5%) incubator.  Half a million 
cells were seeded 24 hours before treatment. DMEM, 500ng/ml of BDNF, Nano-BDNF (Z-/+ 
= 946), or equivalent amount of PEG-PLE polymer in the Nano-BDNF formulation were 
incubated with the cells for 5 minutes at 37oC in serum-free DMEM then moved to ice for 20 
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minutes and lysed using RIPA buffer with proteinase and phosphatase inhibitors. 10ug total 
protein from the cell lysates were loaded in each well of 7.5% TGX pre-cast gels and run at 
150V for 1 hour. Proteins were then transferred to 0.45µm PVDF membranes at 500mA current 
for 1 hour. The membranes were then blocked in either 5% BSA (for detection of 
phosphorylated TrkB and ERK) or 5% non-fat dry milk (for detection of total TrkB and ERK) 
for 30 minutes at RT followed by an overnight incubation at 4 °C with primary antibody. Bands 
were visualized using HRP-conjugated secondary antibodies after incubation with 
SuperSignalTM West Pic Chemiluminescent Substrate for 1 minute. Chemiluminescent signal 
was recorded by a FluorChem™ E series imager, and quantified by Image J software (National 
Institute of Health (NIH), Bethesda, MD) using densitometry analysis. 
4.3.12 Animals. 
Charles River Laboratories supplied 8-week-old male CD-1 mice (24-28 g). Animals 
were housed and humanely handled in accordance with the Principles of Animal Care outlined 
by National Institutes of Health. They were allowed free access to food and water and were 
maintained under temperature, humidity, and light-controlled conditions. Institutional Animal 
Care and Use Committees (IACUC) of the University of North Carolina at Chapel Hill 
approved all experiments involving animal subjects.   
4.3.13 INB administration and pharmacokinetic study. 
 INB administration of 125I-BDNF or 125I-Nano-BDNF was performed by pipetting 
10µL of sample solution (total radioactivity is 1,000,000 cpm, Z ratio is 1100, PEG-PLE 
concentration is 0.91 mg/ml) with a thin tip advanced 5 mm into the left nare of the mice pre-
anesthetized with an intraperitoneal injection of 0.2 mL of 40% urethane. The abdomen and 
rib cage of the mice were opened and venous blood was collected by cardiac puncture at each 
time point (5, 10, and 30 minutes) after INB administration. Next, 20 mL of PBS was perfused 
through the left ventricle of the heart. Mice were quickly decapitated and different brain regions 
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were immediately dissected on ice and weighed. Serum samples were obtained by 
centrifugation of whole blood at 5000g for 10 minutes. Peripheral organs were also collected 
and weighed. Levels of radioactivity in mice serum, brain regions, and peripheral organs were 
measured with a γ-counter.  
4.3.14 BDNF efflux measurement. 
 To measure the rate of BDNF efflux from the brain, the mouse scalp was removed and 
a hole was made into the skull and 1 ul LR containing 500,000 cpm of 125I-BDNF or 125I-Nano-
BDNF was slowly injected into the lateral ventricle of the brain.  Mice were decapitated at 2, 
5, 10, 20 minutes and the whole brain was removed and weighed.   The level of 125I-BDNF 
available for transport at t = 0 was estimated in mice that had been overdosed with urethane for 
20 min and had received an injection of 125I-BDNF 10 min earlier. To determine the residual 
levels of radioactivity in the brain, samples were counted with a γ-counter. 
4.3.15 Statistical analysis.  
Statistical analysis was done using Prism 6.01 software (GraphPad, CA). Statistical 
differences between treatment groups were determined using unpaired Student's t-test for 
groups of two and one-way ANOVA followed by Tukey's multiple comparison test for groups 
of three and above. A P-value less than 0.05 was considered significant. Results of all 
experiments are presented as mean ± SEM unless otherwise specified.  
4.4 Results 
4.4.1 A simple and straightforward nanoformulation. 
Native BDNF forms large and highly heterogeneous aggregates with an effective 
diameter (Deff) of about 600 nm and polydispersity index (PDI) greater than 0.4 (Figure 4.1 A, 
B). Thereby it cannot be used as an injectable pharmaceutical agent without proper formulation. 
Our approach addresses this problem by simple mixing BDNF and PEG-PLE aqueous 
solutions. The Nano-BDNF complexes form spontaneously, without sonication or other 
extensive agitation and are nearly monodisperse with PDI less 0.1 at the charge ratios (Z-/+) 
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from 0.5 to 5 (Figure 4.1 A, C). The polydispersity increases above Z+/- = 5 but still remains 
relatively low. (Here and below we use the charge ratio i.e, the molar ratio of total number of 
glutamic acid residues on PEG-PLE to the total number of lysine and arginine residues on 
BDNF as a parameter defining the composition of Nano-BDNF mixtures). The particle size 
increases from 191 nm to 246 nm as Z+/- changes from 0.5 to 3 and then remains essentially 
constant. The transmission electron microscopy (TEM, Figure 4.2) and atomic force 
microscopy (AFM, Figure 4.3) suggest that Nano-BDNF consists primarily of smaller 
roundish shaped particles, while BDNF forms irregularly shaped aggregates. 
4.4.2 Stoichiometry of the complex formation. 
The stoichiometry of the complex formation was further characterized by horizontal 
agarose gel electrophoresis (HAGE). As expected, native BDNF (known to bind to various 
polysaccharides [233]) does not migrate in the agarose gel and remains immobilized in the well 
(Figure 4.4 A). In contrast, Nano-BDNF migrates towards the anode suggesting that the 
nanoformulation prevents BDNF immobilization on a gel and the complex particles acquired 
negative charge. Since BDNF alone is highly positively charged this indicates that the charges 
are neutralized by PEG-PLE. At a low Z-/+ (lanes 1-10, Figure 4.4 B) Nano-BDNF migrates 
as a diffuse band, which grows as the amount of copolymer increases due to increasing 
complexation of BDNF. We then observe a second species forming (lanes 11-19, Figure 4.4 
B) that is present until saturation, beyond which (lanes 20-24, Figure 4.4 B) we observe only 
one type of the complex species. By plotting the weighted distance of the complex migration 
in the gel over the charge ratio, the saturation Z-/+ in this experiment is determined to be 6.4 
(Figure 4.4 C), suggesting incorporation of a considerable excess of polyanion PEG-PLE. This 
value is further supported by the isothermal titration calorimetry (ITC) results where the 
exothermic reaction between BDNF and PEG-PLE was recorded until Z-/+ of 6.8 is reached 
(Figure 4.5).  
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4.4.3 Molecular dynamics (MD) simulation of the complex formation. 
Disproportioning (simultaneous formation of several distinct types of complexes) and 
overcharging (incorporation of an excess of polyion) is common for polyion complexes when 
interacting species can aggregate due to hydrophobic or other molecular interactions[245]. 
However, the charge excess of PEG-PLE (6 to 7 fold) incorporated in Nano-BDNF seems to 
be unusually high compared to similar complexes of other proteins and nucleic acids. To better 
understand possible molecular interactions between the reacting species we carried out MD 
simulations to model how the charged PEG-PLE associates with the local charge patches on 
the BDNF. We simulated single PEG-PLE chains and a BDNF dimer for 100 ns using four 
starting seed positions (Figure 4.6 A). We observed association and binding in every 
simulation, although the binding at any given residue was transient (Figure 4.6 A-D). The 
interaction interface consists of many residues on BDNF and PEG-PLE that come into close 
contact and are indicative of hydrogen bonding. We used HBplus, a program designed to 
identify and analyze hydrogen bonds, to determine if hydrogen bonds were formed. Indeed, we 
noted that there are residues with high frequency of interaction and H-bond formation with the 
glutamic acid residues of PEG-PLE (Figure 4.7 A, B, Table 4.1). BDNF is a compact globular 
protein consisting of approximately 70% ß-strands and 20% ß-turns [40]. Our simulations 
suggest that the binding sites are located primarily on the highly charged regions of the BDNF 
molecule, characterized by high β-turn/random coil content (Figure 4.7 C). Furthermore, due 
to the distance between the cationic patches (Figure 4.8), a single PEG-PLE chain is unable to 
saturate both sites present in the BDNF dimer (Figure 4.9 A). Hence, we simulated higher 
molar ratios of PEG-PLE to BDNF (Figure 4.9 B-F). Taking into account all H-bonds that can 
occur we demonstrate that the stoichiometry of Nano-BDNF formation is between molar ratio 
of 2 and 3 (equivalent to Z-/+ of 2.3 and 3.4).  
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While the MD simulation serves well to locate the binding sites on BDNF, it does not 
capture the full complexity of the BICs where more than one BDNF molecules actually 
participate in the interaction simultaneously. In context with the DLS data, we noticed that 
Nano-BDNF maintained an extremely narrow size distribution at Z-/+ of 5 (PDI = 0.026), 
suggesting non-cooperative incorporation of free polymers into the micelle at charge ratios 
beyond stoichiometry [31]. At Z-/+ of 10, we started to observe the presence of free PEG-PLE 
in the solution as evidenced by elevated polydispersity (PDI = 0.214), indicating the formation 
of a saturated BIC with Z-/+ between 5 and 10. Hence, we hypothesize that Nano-BDNF can 
recruit free PEG-PLE past stoichiometry and form an overcharged species. Overcharged BIC’s 
have been well documented before, attributing the incorporation of additional host 
polyelectrolytes (PEG-PLE in our case) to a favorable decrease of the free energy in the system 
as a consequence of the redistribution of interpolymeric ionic bonds between the BIC and the 
host polyelectrolyte that is in excess [246-248]. 
4.4.4 Stability of the complexes. 
The nano-stabilization effect could also explain the formation of BIC in an isotonic 
solution like LR. Indeed, high salt concentrations usually lead to dissolution of BICs by 
electrostatic screening of its constituent parts [249]. Although Nano-BDNF prepared at low 
charge ratios (Z-/+ ≤ 3) is able to form in LR, high ionic strength compromises its integrity, 
allowing BDNF to bind agarose (Figure 4.10 A, B). In contrast, overcharged Nano-BDNF (Z-
/+ > 3) resists dissolution in higher ionic strength solutions (Figure 4.10 C, D, E) and a fraction 
is observed migrating even at 1.05 M NaCl.  This fraction of Nano-BDNF features lower 
migration velocity in high ionic strength environments, possibly due to detachment of BDNF 
from the core of the complex and subsequent osmotic swelling of the remaining species which 
are the two typical steps of salt-induced BIC dissolution [248]. Furthermore, an excess of free 
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PEG-PLE (Z-/+ = 100) in the solution decreased the amount of free BDNF that is stripped from 
the BIC, suggesting an easy approach to prepare stable BIC formulations.   
Agarose gel shares several key characteristics with mucus in containing a 
microenvironment that is porous and contains polysaccharide chains. We propose that there is 
similarity in how the nanozymes would travel through the agarose gel and penetrate mucus.   
Mucus as a barrier features a highly glycosylated, porous mucin network which is aided by 
numerous mucosal proteins [250]. Albumin for example, is negatively charged and accounts 
for about 15% of nasal mucosal proteins [251]. While it associates with positively charged 
BDNF after incubation, it showed no interaction with Nano-BDNF (Figure 4.11 C). Similarly, 
serum IgG and secretory IgA do not compromise the integrity of Nano-BDNF as evidenced in 
HAGE experiments (Figure 4.11 A, D). This is likely because of the protective effect of the 
5KDa PEG corona  that is dense enough to shield the hydrophobic core of Nano-BDNF, which 
has been reported to facilitate nanoparticles diffusion through mucus [252].  
4.4.5 Nano-BDNF releases active BDNF without compromising its intrinsic stability 
The greatest challenge of the use of nano-particulate carriers is to deliver an 
uncompromised cargo to a specific location. In context, our objective is to maintain integrity 
of BDNF and release it to the relevant receptor (TrkB) in the brain. We characterized the 
interaction of TrkB and Nano-BDNF by incubating the soluble, recombinant extracellular 
domain of TrkB with BDNF and Nano-BDNF before HAGE experiments. Incubation of Native 
BDNF and TrkB indicated that they associate and migrate together (Figure 4.11 B, Lane 8). 
Similarly, when mixed with Nano-BDNF, TrkB associates in a 1:1 stoichiometry with the 
BDNF dimer and destabilizes the BIC, thus causing the band containing Nano-BDNF to 
proportionally decrease in intensity (Figure 4.11 B).  Moreover, when Nano-BDNF was 
incubated with IgG and IgA at the same molar ratios, no change in the Nano-BDNF smear was 
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observed (Figure 4.11 A, D). Similar effects were observed on a low-affinity BDNF receptor, 
p75NTR. (Figure 4.11 E) 
While it was clear that TrkB could abstract BDNF from the BIC, concerns that BDNF 
was compromised, and thus inactive, remained. Indeed, previous reports indicated that 
interaction with polyelectrolytes can destabilize protein cargos [50-52]. We analyzed the 
protein stability in two distinct assays to determine how the stability and functionality were 
affected. We assayed the melting temperatures (Tm) of BDNF and Nano-BDNF using a 
fluorometric dye which responds to environmental changes, namely, hydrophobicity.  We 
showed that Native BDNF has a Tm value of approximately 83°C (Figure 4.12 A), which is 
consistent with previous reports that BDNF denaturation occurs between 60oC and 90oC [253]. 
Similarly, we demonstrate that Nano-BDNF has a slightly higher stability (~ 0.5°C) at Z-/+ of 
5 and 10 (Figure 4.12 B). In order to determine if functionality was maintained as well, we 
incubated BDNF and Nano-BDNF with NIH 3T3 cells, a cell line which stably expresses TrkB 
and does not produce BDNF. Activation of TrkB was tested using a phosphospecific antibody 
to detect the phosphorylated TrkB kinase domain. TrkB phosphorylation is observed at the 
same level when stimulated with BDNF and Nano-BDNF, indicating that the vehicle does not 
inhibit activity or association (Figure 4.13 A). Phosphorylated ERK, a downstream target 
kinase [254], was also observed at similar levels after TrkB stimulation with BDNF and Nano-
BDNF (Figure 4.13 B) [53, 54].  
4.4.6 Nano-BDNF significantly enhanced the delivery of BDNF to brain regions after 
INB administration. 
We next performed an in vivo pharmacokinetic study to evaluate the ability of this 
formulation to deliver BDNF to the brain after INB administration, which is known to rapidly 
deliver therapeutic proteins to a wide range of brain regions [228]. Indeed, in most of the brain 
regions, both native and nanoformulated 125I-BDNF was readily detected as soon as 5 min. 
after INB administration (Figure 4.14). Within 30 min. after INB administration, the level of 
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Nano-BDNF accumulation in the brain was significantly higher than that of the native BDNF 
in all studied brain regions, except for midbrain, where there was a trend for the increase. 
Comparing the areas under the curve (AUC) 0 to 30 min for the native BDNF and Nano-BDNF 
suggests that the nanoformulation increases the delivery of the neurotrophin in all these 
regions, notably in the olfactory bulb (6.7 times), hippocampus (9.9 times), and brainstem 
(~4.0 times) (Figure 13B and Supplementary Table S2). The overall increase for the whole 
brain was as also significant albeit less dramatic (3.5 times) (Table 4.2). By dividing the areas 
under the curve (AUC) for different brain regions we further concluded that relative to the 
native BDNF, the brain regional distribution pattern of Nano-BDNF was very different. 
Specifically, there was an increase of the Nano-BDNF distribution to hippocampus vs. 
olfactory bulb, hypothalamus and the rest of the brain (Figure 4.15). In contrast, the 
distribution to pons and medulla was only slightly increased vs. to the rest of the brain, while 
the relative distribution to the midbrain was decreased vs. both olfactory bulb and the rest of 
the brain.   
We also show that the amount of Nano-BDNF distributed in the serum after intranasal 
administration was lower than the native BDNF (Table 4.2). Analysis of the peripheral 
distribution of Nano-BDNF suggests that within 30 min following INB delivery, Nano-BDNF 
was detected in liver, spleen, kidney, lung and heart – albeit at levels less than 0.5% inj/g. 
Marginally higher amounts of the INB delivered Nano-BDNF were found in the esophagus, 
trachea, and stomach but these amounts still were in the range of 1-2% inj/g tissue (Figure 
4.16) and were likely due to limitations of our INB procedure in a mouse (“post nasal drip”).  
In addition, literature [217] as well as our own studies suggest that there is a brain-to-blood 
efflux mechanism for native BDNF. However, we observed much less efflux of Nano-BDNF 
from brain to blood when it was directly injected to cerebral ventricle (ICV) relative to native 
BDNF (Figure 4.17). This observation may help to explain why despite the increased 
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accumulation of Nano-BDNF in the brain, its release into the serum was not increased to the 
same extent.  
The serum clearance and brain uptake of Nano-BDNF after intravenous (IV) 
administration is shown in Figure 4.18.Consistent with ICV data IV Nano-BDNF displays 
decreased efflux and greater brain uptake than the native BDNF. Comparing the Brain/Serum 
ratios for IV (~60 to 80 μl/g) and INB (~1000 to 3000 μl/g) Nano-BDNF suggests that blood 
to brain route could explain only ~2 to 8% of whole brain uptake of Nano-BDNF after nasal 
administration. Overall, our data suggest that Nano-BDNF delivered by the INB route has 
improved delivery to regions of the brain (the brainstem and hippocampus) that are important 
targets for RTT therapeutics. Moreover, the relatively low distribution to the blood and 
peripheral organs should decrease the risk of side effects associated with systemic exposure to 
Nano-BDNF. Taken together our data represent a compelling rationale for advancing the 
development of Nano-BDNF as a treatment for this disease. 
Passage of therapeutic proteins from nose to brain is known to be associated with at least two 
pathways: the peripheral olfactory system pathway (transporting to the olfactory bulb and 
rostral brain regions), or the peripheral trigeminal system pathway (transporting to the brain 
stem and caudal brain regions) [228]. The distribution pattern of native BDNF suggests the 
shorter, olfactory-associated pathway is its primary route, whereas Nano-BDNF appears to use 
both pathways to enter the brain (Figure 13A). We postulate this is due to reduced binding to 
the brain extracellular matrix and increased diffusion rates of BDNF as a result of encapsulation 
inside PEG-coated nanoparticles [255].  
Higher accumulation of BDNF in the BIC formulation could also be related to 
decreased efflux from brain to the blood. Indeed, BDNF is known to be transported from the 
brain to the blood in association with the reabsorption of the cerebral spinal fluid [217]. A 
recent report has shown that the distribution of INB administered therapeutic proteins in the 
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brain is carried by bulk flow within the perivascular space (PVS) of cerebral blood vessels 
[229] where CSF plays an important role in the clearance of substances [256].  Therefore, we 
hypothesize that Nano-BDNF could reduce the rate of BDNF efflux. This hypothesis is tested 
by intracerebroventricular (ICV) injection of 125I-BDNF into the mouse brain followed by 
measurement of its radioactivity in the brain at different time points after injection (Figure 
4.17). Consistent with our hypothesis, we observed significantly slower efflux rate of Nano-
BDNF from brain to blood as compared to that of native BDNF.   
4.5 Conclusion 
In this manuscript, we present a simple and readily translational formulation of BDNF. 
As a protein delivery system, Nano-BDNF remains stable in high salt concentrations, protects 
BDNF from non-specific binding within the environment, and readily releases active BDNF 
upon interaction with its receptor. Most current nanoparticulate formulations of BDNF (PLGA 
microspheres [257], nanoporous PLE particles [258], hydrogel scaffolds[259]) controls its 
release temporally, ie. sustained release during a period of time. In contrast, Nano-BDNF 
releases BDNF in a spatially controlled manner. That is, the release of BDNF is triggered by 
the presence of a BDNF receptor. At the same time, Nano-BDNF maintained the advantages 
of PEGylated nanoparticles in terms of cargo protection and mucus penetration. The delivery 
of Nano-BDNF significantly increased BDNF accumulation in a variety of brain regions via 
the INB route, and decreased the efflux rate of BDNF from brain to blood after ICV injection. 
4.6 Future directions 
In this chapter we focused our research on the composition of Nano-BDNF and its 
application for intranasal-to-brain delivery. We are also interested in exploring the possibility 
of using this formulation for BDNF delivery via the IV route. During my graduate study, I have 
also contributed to some experiments led by Dr. Xiang Yi to explore PK differences between 
native BDNF and Nano-BDNF after IV administration. This is a big part of our plan for the 
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future of this project. Some of these data has already been incorporated in the main text of this 
dissertation (Figure 4.17, Figure 4.18), but others were not since they were not relevant to the 
intranasal delivery story. We have also worked in collaboration with Dr. Rajkumar Verma to 
demonstrate preliminary therapeutic efficacy of Nano-BDNF in stroke (Pharmacol Biochem 
Behav. 2016 Sep 13;150-151:48-56. doi: 10.1016/j.pbb.2016.09.003). Here I’m incorporating 
the preliminary data obtained from experiments led by Dr. Xiang Yi (APPENDIX I) and the 
abstract of the published paper from Dr. Rajkumar Verma’s work (APPENDIX II) in the 
appendices of this dissertation for completeness. 
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Figure 4.1 Dynamic light scattering. 
A. Effective diameter of native BDNF and Nano-BDNF samples prepared at different Z-/+ 
values were measured with DLS.  The Z-averaged diameter was plotted to the left Y-axis, and 
the PDI was plotted to the right Y-axis (n = 5). Statistical significance is defined as P < 0.05, 
and indicated by: *, p < 0.05; **, p < 0.01; B-C. Representative intensity-size graphs of native 
BDNF and Nano-BDNF (Z-/+ = 5).  
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Figure 4.2 Representative TEM images. 
A. native BDNF and B. Nano-BDNF (Z-/+ = 10).  
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Figure 4.3 Representative AFM pictures. 
Phase diagrams (A,B) and 3D topographies (C,D) of native BDNF (A,C) and Nano-BDNF (Z-
/+ = 10, B, D).  
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Figure 4.4 Horizontal agarose gel electrophoresis. 
A. The electrophoretic mobility of PEG-PLE (lane 1), Native BDNF (lane 2) and Nano-BDNF 
(Z-/+ = 100, lane 3) were determined by running on a 0.5% agarose gel (pore size around 500nm 
[260]) at 80V for 1 hour. Samples were loaded in the rectangular wells indicated by the black 
triangle. The “-” and “+” signs denote cathode and anode, respectively. The black arrow 
indicates direction of electron flow.  Commassie Blue staining was performed to visualize 
BDNF, since it has minimal staining of free PEG-PLE copolymer. Despite the positive charge 
on BDNF at the pH of the running buffer, a small fraction of BDNF was always observed to 
migrate towards the anode, possibly due to binding and subsequent charge-conversion by free 
agarose oligomers and/or polymers that are not completely immobilized in the gel. B. The 
electrophoretic mobility of Nano-BDNF prepared at different Z-/+ values were evaluated and 
presented in the same way as described in A. Lanes 1–24 represent samples with different Z-/+ 
values from 0 to 25. C. To quantify the migration distance of BDNF, we located the center of 
mass of the BDNF smear in each lane of B. and measured its distance from the loading well of 
that lane. The distances were then quantified and normalized with the value obtained at Z-/+ = 
25 being 100% and plotted against their Z-/+ values on a logarithmic scale. A sigmoidal curve 
was fitted to the plot, and the minimum saturation Z-/+ value “S” was determined to be about 
6.4 by elongating and intersecting the two linear portions of the curve on the graph.  
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Figure 4.5 ITC measurement of complexation process between BDNF and PEG-PLE 
ITC data obtained by slowly titrating PEG-PLE solutions into an isothermal chamber 
containing BDNF corroborates the saturation Z-/+ of Nano-BDNF to be between 6 and 7. 
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Figure 4.6 Molecular dynamics simulation. 
A. Simulations were prepared with PEG-PLE in various starting positions (Boxed Polymers).  
B. Final frames of all the trajectories indicated tight binding between BDNF (visualized in 
cartoon mode) and PEG-PLE (visualized in stick mode) resulted from the simulations. C. 
Magnified picture of the squared area shown in B. The amino acids on BDNF that are within 
3.9 Å of a glutamic acid residue on PEG-PLE are visualized in stick mode. D. Magnified 
picture of the squared area shown in C. Two hydrogen atoms on Arginine 69 of BDNF are 
shown to be located within 2 Å of oxygen atoms on PEG-PLE. 
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Figure 4.7 Binding site determination. 
A. Frequency map of BDNF-polymer interactions on each amino acid of BDNF. The frequency 
levels of hydrogen bonds and Non-bonding contacts are determined separately based on their 
total counts (summarized in table 1) in the trajectories obtained from 4 independent simulations 
with 1 BDNF dimer and 1 PEG-PLE chain. B. Quantification of BDNF – polymer interaction 
occurring on β-strands versus other structural domains. The result is presented as the number 
of occurrences averaged by the number of amino acids (denoted by AA in the figure) forming 
each structural domain. “*” denotes statistical significance between two groups (P < 0.05). C. 
Cartoon visualization of a BDNF dimer molecule with illustrations of predominant structural 
domains at each part of the protein. The red meshes represent amino acids that are actively 
involved in the binding between BDNF and its receptor, TrkB.  
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Figure 4.8 Identification of charge patches on BDNF and 3D density map of BDNF 
binding sites with PEG-PLE. 
A. Electrostatic potential of BDNF plotted on the solvent-accessible surface. Potential surfaces 
are visualized (-5KbT/ec (red) and +5KbT/ec (blue) around a BDNF dimer molecule at pH 7, 
calculated with APBS tool 2.1. The two major cationic cavities are highlighted with the dashed 
circles. B. 3D-Heatmap of BDNF-polymer hydrogen bonds on each amino acid of BDNF. 
Frequency levels were defined in the same way as shown in Figure 3; C. Top view of B.; D. 
Bottom view of B. Frequency levels in B, C, and D are defined as described in Table 4.1. 
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Figure 4.9 Molecular dynamics simulation of 1 BDNF molecule binding to different 
number of PEG-PLE chains. 
A-F. Final frames of simulations with 1 BDNF molecule binding to 1, 2, 3, 4, 6, and 20 PEG-
PLE chains, respectively. The number of hydrogen bonds occurred during the simulation were 
plotted against time: blue curves represent the total number of hydrogen bonds between BDNF 
and all polymer chains in the simulation; black, green, and red curves each represent the 
number of hydrogen bonds formed between BDNF and one single polymer chain. Green: 
cartoon and surface illustrations of a BDNF dimer molecule; Blue: stick illustration of PEG; 
Red: stick illustration of PLE. The number of hydrogen bonds formed was plotted as a function 
of simulation time under each graph. In all simulations a maximum number of 3 polymer chains 
were observed to be able to form hydrogen bonds with the BDNF dimer. 
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Figure 4.10 NaCl and TrkB challenge studies. 
A-E. Nano-BDNF samples of different Z-/+ values (1, 3, 5, 10, and 100, as indicated in the 
graphs) were prepared in NaCl solutions before horizontal agarose gel electrophoresis. The 
concentration of NaCl in the Nano-BDNF samples gradually increased from lane 1 to lane 8 
(0M, 0.15M, 0.30M, 0.45M, 0.60M, 0.75M, 0.90M, and 1.05M, respectively). The amount of 
free BDNF in each experimental condition can be estimated by the staining at the edge of the 
respective loading well.  
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Figure 4.11 Nano-BDNF protects BDNF from challenges of nasal defensive proteins, 
while readily releasing BDNF upon incubation with the BDNF receptors, TrkB and p75. 
Different competitors, including nasal mucosal proteins (A. IgG, C. HSA, D. sIgA), and BDNF 
receptors (B. TrkB, E. p75NTR) were incubated with Nano-BDNF (Z-/+ = 200) in LR for 30 
minutes before subjected to horizontal agarose gel electrophoresis. From left to right, lane 1: 
Competitor; lane 2: Nano-BDNF; lane 3: Competitor incubated with Nano-BDNF (molar ratio 
0.25 : 1); lane 4: Competitor incubated with Nano-BDNF (molar ratio 0.5 : 1); lane 5: 
Competitor incubated with Nano-BDNF (molar ratio 0.75 : 1); lane 6: Competitor incubated 
with Nano-BDNF (molar ratio 1:1); lane 7: Competitor incubated with PEG-PLE (same 
amount as in lane 6); lane 8: Competitor incubated with native BDNF (molar ratio 1:1). Red 
arrows indicate the location of Nano-BDNF bands in each graph. 
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Figure 4.12 Protein thermal shift assay. 
A. A representative graph demonstrating the melting curve of native BDNF in the proprietary 
assay buffer in the Protein Thermal Shift™ Dye Kit. The red dots denote fluorescent signal 
intensity (left Y-axis), and the black triangles denote the negative first-order derivative of 
fluorescent signal intensity (right Y-axis) in the temperature range of 70oC to 95oC. The Tm of 
native BDNF was determined to be 83.16 ± 0.09oC as described in the methods section. B. 
Scatter bar plot summarizing the Tm value of native BDNF and Nano-BDNF at Z-/+ = 1, 5, and 
10 (n = 12). Symbols above the horizontal lines denote significance levels compared to the 
native BDNF group, and are indicated by * (P < 0.05) and **** (P <  0.0001). 
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Figure 4.13 Densitometry quantitation of Western blots for lysates from NIH 3T3 cells 
stably expressing TrkB receptor. 
A. Western blots showing the level of TrkB receptor phosphorylation at the site of Tyrosine 
515 after treatment with (from left to right) DMEM, PEG-PLE, Nano-BDNF or BDNF for 5 
minutes at 37oC (n = 6). Quantification of band density was presented by the ratio of 
phosphorylated TrkB over total TrkB.; B. Western blots showing the level of ERK 
phosphorylation in the same of samples as described in A. Data were analyzed with unpaired 
Student’s t-test between each two groups; *** denotes p<0.001, and n.s. denotes no significant 
difference. 
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Figure 4.14 Uptake of 125I-BDNF and 125I-Nano-BDNF in different brain regions over 
30 min after IN delivery. 
A. Heatmap demonstrating the area under the curve (AUC) of BDNF or Nano-BDNF exposed 
to different brain regions over a period of 30 min. after INB administration. B. Significant 
differences in the accumulation at a variety of brain regions was observed between BDNF and 
Nano-BDNF.  
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Figure 4.15 Nano-BDNF distribution in different brain regions after INB delivery 
compared to native BDNF. 
Data present AUC ratios for the hippocampus (HC), pons (PON) and medulla, and midbrain 
(MB) vs. olfactory bulb (OB), hypothalamus (HT), and “rest of the brain” (RB) defined as all 
brain regions excluding HC and brainstem. 
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Figure 4.16 Peripheral organ distribution of Nano-BDNF following INB delivery. 
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Figure 4.17 Inhibition of BDNF efflux from the brain to the blood. 
Brain efflux curves of 125I-BDNF or 125I-Nano-BDNF after ICV injection showing the rate of 
efflux, as indicated by the slopes of the lines were −0.012 ± 0.0014 (r2 = 0.89, n = 26) for 
BDNF and −0.0018 ± 0.0023 (r2 = 0.07, n = 30) for Nano-BDNF, respectively. Both slopes 
were significantly non–zero and differences between the slopes are extremely significant. 
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Figure 4.18 Brain PK of IV Nano-BDNF. 
A.  Nano-BDNF clears from the circulation similarly to native BDNF; B. Nano-BDNF displays 
net influx (Ki = 0.84 uL/g.min) into the brain, whereas native BDNF displays a net efflux from 
brain to the blood; C. Nano-BDNF displays higher brain uptake than native BDNF, as shown 
by AUC of 2.96 for Nano-BDNF vs 0.54 for native BDNF. The native BDNF or Nano-BDNF 
were injected IV at a single dose of 0.5 μg/mouse. 
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Table 4.1 Reference chart for the frequency levels shown in Figure 4.7 and Figure 4.8. 
Frequency 
level 
 Count_NC Count_HB 
0  0 - 100 0 - 100 
1  100 - 1000 100 - 1000 
2  1000 - 5000 1000 - 2000 
3  5000 - 10000 2000 - 3000 
4  10000 - 20000 3000 - 4000 
5  > 20000 > 4000 
Count_NC denotes the total number of non-bonding contacts, and Count_HB denotes the total 
number of hydrogen bonds formed across the entire process of the four simulation experiments. 
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Table 4.2 Summary of BDNF AUC values (%inj·min/g) in different brain regions). 
Region BDNF Nano-BDNF Ratio 
Olfactory 5.094 34.32 6.7 
Striatum 1.860 4.923 2.6 
Frontal Cortex 0.8850 2.033 2.3 
Hypothalamus 2.145 9.588 4.5 
Hippocampus 0.7300 7.229 9.9 
Thalamus 0.6150 4.419 7.2 
Parietal Cortex 0.6200 2.261 3.6 
Occipital Cortex 0.9400 2.593 2.8 
Cerebellum 0.9200 1.704 1.9 
Midbrain 0.9500 1.929 2.0 
Pons 0.7917 3.220 4.1 
*Whole Brain 1.020 3.550 3.5 
**Brainstem 0.7289 2.905 4.0 
Serum 4.835 3.088 0.6 
* Whole brain AUC was calculated as the weight-averaged AUC of all the brain regions listed above 
(except brainstem). 
** Brainstem AUC was calculated as the weight-averaged AUC of midbrain and pons regions. 
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CHAPTER 5 SUMMERY AND FUTURE DIRECTIONS 
In this thesis, I reviewed the history of block ionomer complexes and introduced its 
applications in the field of protein delivery. Limitations with this formulation to be used as an 
in vivo protein delivery carrier are summarized, and different approaches to overcome these 
limitations are discussed. 
Stability of protein block ionomer complexes in vivo is one of the biggest obstacles for 
their development and application. The formulation of SOD1 nanozyme addresses this problem 
by chemical crosslinking. This approach is useful for the delivery of SOD1 because this 
enzyme does not need to be released in order to function. Its substrate, superoxide anions, are 
small enough to penetrate into the core of the complex using a concentration gradient and get 
removed by the active enzyme encapsulated at the core. For stroke ischemic-reperfusion injury, 
this formulation was remarkably effective due to their passive accumulation at the injured sites 
on brain capillaries and arteries after stroke. By locally staying at the region where superoxide 
anions are generated for the entire length of blood vessel damage, this formulation is ideal for 
the treatment of similar pathologies involving vasculature damage. For example, ischemic-
reperfusion injuries also occur in the case of myocardial infarction, and after organ 
transplantation; other similar conditions include the vascular damage after cancer radiotherapy. 
For the treatment of chronic diseases which involve frequent dosing regimens, the PLL 
polymer can be replaced by more biocompatible polymers, e.g. PAsp(DET), to avoid the 
toxicity associated with this highly cationic polymer. Furthermore, surface modifications by 
antibodies can be introduced to this formulation for more specific targeting towards different 
tissues of interest. 
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The BIC formulation formed with BDNF and PEG-PLE polymer represent another 
direction of our research by exploring the nature of molecular interactions driving the complex 
to form. It is widely accepted that hydrogen bonding and hydrophobic interactions can 
contribute to the formation and stability of BICs, and we can possibly design more stable BICs 
by taking advantage of these forces after fully understanding the natural laws governing them. 
Molecular modeling is a powerful tool for us to move this research forward, as well as the state 
of art biophysical research tools previously utilized to understand protein structures and 
interactions. 
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APPENDIX I 
Brain PK study using therapeutic dose of BDNF shows that Nano-BDNF clears from 
circulations similar to native BDNF. 
Brain PK study BDNF shows that Nano-BDNF clears from the circulation similarly to 
native BDNF. Nano-BDNF displays net influx (Ki = 0.84 uL/g.min) into the brain, whereas 
native BDNF displays a net efflux from brain to the blood. Consequently, Nano-BDNF 
displays higher brain uptake than native BDNF, as shown by AUC of 2.96 for Nano-BDNF 
vs 0.54 for native BDNF. The native BDNF or nano-BDNF were injected IV at a single dose 
of 0.5ug BDNF per mouse co-injected with 125I-BDNF tracers. 
 
Figure 1. (A); Nano-BDNF rapidly enters the brain, whereas native BDNF displays an efflux 
from brain to the blood, as indicated by the influx rate (Ki) of Nano-BDNF across the BBB at 
0.84 uL/g.min (B); and consequently nano-BDNF displays higher brain uptake than native 
BDNF, as shown by AUC of 2.96 for Nano-BDNF vs 0.54 for native BDNF (C). 
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Nano-BDNF remains intact in brain but less stable in serum 
 
Figure 2. Nano-BDNF is less stable than native BDNF in serum at early time point (10 min) 
but remains similar intactness as native BDNF in the brain. The stability was accessed by the 
percent of radioactivity precipitated in the pellet and normalized by the values for processing 
controls (n=2/time point, * p < 0.05).  
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Capillary depletion study shows that at least half of Nano-BDNF is detected in brain 
parenchyma, indicating Nano-BDNF crosses the BBB and accumulates in the brain side.  
 
Figure 3. No difference was observed in amount between the capillary-associated BDNF and 
parenchyma-associated BDNF. 
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The amount of BDNF delivered by the same dose of PLE-PEG solution peaks at 5ug. 
 
Figure 4. Different doses (0.5ug, 5ug, 10ug, and 20ug) of BDNF were mixed with 200ul of 
1mg/ml PLE-PEG solution in LR, resulting in Nano-BDNF complex formed at different Z 
ratios (946, 94.6, 47.3, and 23.7, respectively). The solutions were then IV injected in 
experiment mice and their brain/serum ratios were measured (A) and absolute delivery values 
were calculated (B). The result suggests 5ug as the most appropriate dose for in vivo delivery 
in this mouse model. 
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Brain uptake of Nano-BDNF is polymer-dose dependent 
 
Figure 5. Nano-BDNF formed at various PEG-PLE concentrations (Nano-BDNF(0.1%) to 
(0.002%)) display significantly different brain PK profiles. Brain uptake of these 3 
formulations, as shown by AUC of %inj/g of BDNF over 10 min following i.v. injection is 
2.48, 1.20 and 1.03 respectively. 
  
127 
Nano-NGF Brain PK shows similar pattern to that of BDNF.  
  
Figure 6. Brain PK study using trace amount of iodinated NGF substance shows that Nano-
NGF greater of BBB penetration than native NGF. 
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PGA-PEG labeled with Cu-64 shows rapid brain influx 
 
Figure 7. PEG-PLE polymer was labelled with Cu-64 and its brain influx rate was measured. 
The labelling was performed at the N-terminal of the PEG-PGA polymer, with help from Dr. 
Zibo Li, UNC Chapel Hill. PEG-PLE appears to be transported across BBB pretty fast. 
However, we don’t know if it is transported as an intact polymer, or is it just the free glutamic 
acid being transported after degradation. To this end, TCA precipitation was done in the brain 
tissue, and assured the intactness of labelling.  
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APPENDIX II 
Pharmacological validation of neuroprotection by BDNF nano-particles after focal 
cerebral ischemia in mice5 
Reduced brain-derived neurotrophic factor (BDNF) levels have been associated with 
delayed neurological recovery, depression, and cognitive impairment following stroke, 
whereas supplementation reverses these impairments. Unfortunately, systemically 
administered BDNF in its native form has minimal therapeutic value due to its poor blood brain 
barrier permeability and short serum half-life. In this study, a novel nano-particle formulation 
of BDNF was used to evaluate potential neuroprotective efficacy after experimental stroke. 
Male C57BL/6J (8-10 weeks) mice were randomly assigned to one of three treatment groups 
after being subjected to 60 minutes of reversible middle cerebral artery occlusion (MCAo) 
followed by 14 days of reperfusion. Mice in Group A (early treatment) were treated twice with 
either BDNF nano-particles (nano-BDNF) or saline (250µg/kg i.v; n=6/group) 3 and 24 hours 
after the onset of MCAo. Mice in Groups B (intermediate treatment) and C (delayed treatment) 
were treated twice with saline, native-BDNF, or nano-BDNF (250µg/kg i.v.; n=8/group) 6 and 
24 (B) or 12 and 24 (C) hours after MCAo, respectively. Early and intermediate nano-BDNF 
treatment led to a significant reduction in tissue loss compared to native-BDNF and saline 
treatment. Additionally, mice in Group A showed rapid recovery from stroke-induced 
neurological deficits. Delayed treatment (Group C) led to improved memory/cognition and 
reduced post-stroke depressive phenotypes, but had no effect on tissue atrophy. Collectively, 
our results indicate that nano-particle formulations of BDNF show neuroprotective effects even 
with delayed treatment. This study suggests that nano-BDNF treatment has therapeutic 
potential with a wide treatment window.  
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